

79 ACTUALS

FMB



National Cancer Institute

1979 NCI FACT BOOK

U. S. DEPARTMENT OF
HEALTH AND HUMAN
SERVICES

Public Health Service

National Institutes
of Health

NATIONAL CANCER PROGRAM

National Cancer Institute

1979 NCI FACT BOOK



Revised December 1979
NIH Publication No. 80-512
April 1980

U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service National Institutes of Health

PREFACE

The information set forth in this publication is compiled and amended annually by the Financial Management Staff of the National Cancer Institute and is intended primarily for use by members of the Institute staff, the principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Manager, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland 20205.

TABLE OF CONTENTS

| | PAGE |
|--|------|
| Preface | ii |
| GENERAL INFORMATION | |
| Directory of Personnel | iv |
| Historical Data: Legislative Highlights | 1 |
| Historical Events | 2 |
| Director, NCP/NCI—President's Cancer Panel | 3 |
| NCI Executive Committee | 4 |
| National Cancer Advisory Board | 5 |
| Organizational Tables: National Cancer Institute | 6 |
| Office of the Director | 7 |
| Division of Cancer Cause and Prevention | 8 |
| Division of Cancer Biology and Diagnosis | 9 |
| Division of Cancer Treatment | 10 |
| Division of Cancer Research Resources and Centers | 11 |
| Division of Cancer Control and Rehabilitation | 12 |
| Total National Resources for Cancer Research and Cancer Control—Fiscal Year 1979 | 13 |
| National Cancer Program Strategy | 14 |
| Actual vs. Constant Dollar Funding | 15 |
| Statistical Tables: Mortality for the Five Leading Cancer Sites | |
| Relationship of Cancer to Leading Causes of Death | 16 |
| Estimated Cancer Deaths and New Cases by Sex and Site | 17 |
| Research Positions at the National Cancer Institute | 18 |
| Building Location and Square Footage | 20 |
| BUDGET DATA | |
| NCI Budget Administration Process | 21 |
| National Cancer Institute Budget History by Mechanisms | 22 |
| NCI Extramural Funds—FY 1979 | 24 |
| NCI Research Programs—Fiscal Year 1979 | 25 |
| Total NCI Dollars by Mechanisms—Fiscal Year 1979 | 26 |
| NCI Program Structure—Fiscal Year 1979 | 27 |
| Cancer Control Obligations—Fiscal Years 1973-1979 | 28 |
| Reimbursement to NIH Management Fund—Fiscal Year 1979 | 29 |
| GRANTS AND CONTRACTS | |
| NCI Grants Administration Process—Under Cancer Act of 1971 | 30 |
| NCI Contracts Administration Process—Under Cancer Act of 1971 | 31 |
| State Distribution of NCI Grant and Contract Dollars—Fiscal Year 1979 | 32 |
| State Distribution of Cancer Control Grant and Contract Dollars—Fiscal Year 1979 | 33 |
| Institutions Receiving More Than \$1,000,000 from the NCI—Fiscal Year 1979 | 34 |
| Distribution of NCI Contract Dollars—Fiscal Year 1979 | |
| By Program | |
| By Institution | 36 |
| Distribution of NCI Research Grants by Value of Grant Award—Fiscal Year 1979 | 37 |
| Distribution of the "Grant Dollar"—Fiscal Year 1979 | 38 |
| Foreign Research Grants and Contracts—Fiscal Year 1979 | 39 |
| HISTORY TABLES | |
| Appropriations of NCI—1938-1980 | 40 |
| Distribution of Personnel by Function—1970-1979 | 41 |
| Comparison of Dollars, Positions and Space—1971-1979 | 42 |
| NCI Obligations and Expenditures—1972-1979 | 43 |
| NCI Grant Awards—1970-1979 | 44 |
| NCI Regular Grant Awards—1972-1979 | 45 |

DIRECTORY OF PERSONNEL**NATIONAL CANCER INSTITUTE
NATIONAL INSTITUTES OF HEALTH
BETHESDA, MARYLAND 20014****NIH Operator
496-4000
Area Code 301**

| | | DIRECT-IN DIALING |
|---|------------------------------|------------------------------|
| DIRECTOR | BUILDING 31 | |
| Dr. Vincent T. DeVita, Jr., Acting | 11-A-52 | 496-5615 |
| ASSISTANT DIRECTOR | BUILDING 31 | |
| Dr. Bayard H. Morrison III | 11-A-51 | 496-3308 |
| ASSISTANT DIRECTOR | BUILDING 31 | |
| Dr. Richard A. Tjalma | 11-A-46 | 496-5854 |
| ASSOCIATE DIRECTOR FOR CANCER CENTERS | WESTWOOD BUILDING | |
| Dr. William D. Terry, Acting | 828..... | 496-7991 |
| ASSOCIATE DIRECTOR FOR PROGRAM PLANNING AND ANALYSIS | BUILDING 31 | |
| Mr. Louis M. Carrese | 11-A-49 | 496-6445 |
| CHIEF, PROGRAM ANALYSIS AND FORMULATION BRANCH | BUILDING 31 | |
| Mr. Louis M. Carrese, Acting | 11-A-49 | 496-6445 |
| CHIEF, SYSTEMS PLANNING BRANCH | BUILDING 31 | |
| Ms. Barbara Murray, Acting | 10-A-49 | 496-5515 |
| ASSOCIATE DIRECTOR FOR MEDICAL APPLICATIONS OF CANCER RESEARCH | BUILDING 31 | |
| Dr. Diane J. Fink, Acting | 11-A-29 | 496-1316 |
| ASSOCIATE DIRECTOR FOR CANCER COMMUNICATIONS | BUILDING 31 | |
| Mr. J. Paul Van Nevel | 10-A-29 | 496-6631 |
| CHIEF, INFORMATION RESOURCES BRANCH | BUILDING 31 | |
| Mr. J. Paul Van Nevel, Acting | 10-A-29 | 496-6631 |
| CHIEF, REPORTS AND INQUIRIES BRANCH | BUILDING 31 | |
| Dr. Robert M. Hadsell, Acting..... | 10-A-25A | 496-6641 |
| CHIEF, INFORMATION PROJECTS BRANCH | BUILDING 31 | |
| Ms. Elaine Bratic, Acting | 4-B-39 | 496-6793 |
| ASSOCIATE DIRECTOR FOR INTERNATIONAL AFFAIRS | BUILDING 31 | |
| Dr. Robert W. Miller, Acting | 11-A-19 | 496-4761 |
| ASSOCIATE DIRECTOR FOR ADMINISTRATIVE MANAGEMENT | BUILDING 31 | |
| Mr. Calvin B. Baldwin, Jr., Executive Officer | 11-A-46 | 496-5737 |
| Mr. Robert M. Namovicz, Deputy Executive Officer..... | BUILDING 31 11-A-46 | 496-5737 |
| CHIEF, ADMINISTRATIVE SERVICES BRANCH | BUILDING 31 | |
| Mr. Thomas L. Kearns | 11-A-29 | 496-5801 |
| CHIEF, FINANCIAL MANAGEMENT BRANCH | BUILDING 31 | |
| Mr. John P. Hartinger | 11-A-18 | 496-5803 |
| CHIEF, PERSONNEL MANAGEMENT BRANCH | BUILDING 31 | |
| Mrs. Elizabeth Stroud..... | 3-A-19 | 496-3337 |
| CHIEF, RESEARCH CONTRACTS BRANCH | BUILDING 31 | |
| Mr. James E. Graalman | 4-A-31 | 496-3573 |
| CHIEF, MANAGEMENT POLICY BRANCH | BUILDING 31 | |
| Mr. Paul H. Schaffer, Acting..... | 4-A-51 | 496-6985 |

**DIRECT-IN
DIALING**

| | | |
|---|----------------------------|----------------|
| FREDERICK CANCER RESEARCH CENTER | FREDERICK, MARYLAND | |
| SCIENTIFIC COORDINATOR | BUILDING | |
| Dr. William W. Payne | 427 | FTS-8-935-7305 |
| ADMINISTRATIVE OFFICER | BUILDING | |
| Mr. Richard Carter | 427 | FTS-8-935-2021 |

| | | |
|--|--------------------|----------|
| DIRECTOR, DIVISION OF CANCER CAUSE AND PREVENTION | BUILDING 31 | |
| Dr. Gregory T. O'Connor | 11-A-03 | 496-6618 |
| ADMINISTRATIVE OFFICER | BUILDING 31 | |
| Mr. John M. Miller | 11-A-11 | 496-6556 |

| | | |
|---|--------------------|----------|
| DIRECTOR, DIVISION OF CANCER BIOLOGY AND DIAGNOSIS | BUILDING 31 | |
| Dr. Alan S. Rabson | 3-A-03 | 496-4345 |
| ADMINISTRATIVE OFFICER | BUILDING 31 | |
| Mr. Larry D. Willhite, Acting | 3-A-05 | 496-3381 |

| | | |
|---|--------------------|----------|
| DIRECTOR, DIVISION OF CANCER TREATMENT | BUILDING 31 | |
| Dr. Saul A. Schepartz, Acting | 3-A-52 | 496-4291 |
| ADMINISTRATIVE OFFICER | BUILDING 31 | |
| Mr. Michael Goldrich, Acting | 3-A-50 | 496-5964 |

| | | |
|--|--------------------------|----------|
| DIRECTOR, DIVISION OF CANCER RESEARCH RESOURCES AND CENTERS | BUILDING 31 | |
| Dr. Thomas J. King | 10-A-03 | 496-5147 |
| ADMINISTRATIVE OFFICER | BUILDING 31 | |
| Ms. Jean Stein | 10-A-10 | 496-5915 |
| CHIEF, GRANTS ADMINISTRATION BRANCH | WESTWOOD BUILDING | |
| Mr. Leo F. Buscher, Jr. | 8-A-18 | 496-7753 |

| | | |
|--|-----------------------|----------|
| DIRECTOR, DIVISION OF CANCER CONTROL AND REHABILITATION | BLAIR BUILDING | |
| Dr. William D. Terry, Acting | 732A | 427-7997 |
| ADMINISTRATIVE OFFICER | BLAIR BUILDING | |
| Mr. Hugh E. Mahanes | 730 | 427-7965 |

NATIONAL CANCER INSTITUTE HISTORICAL DATA

LEGISLATIVE HIGHLIGHTS

March 7, 1928—Senator M. M. Neely introduced S. 3554, “To authorize the National Academy of Sciences to investigate the means and methods for affording Federal aid in discovering a cure for cancer and for other purposes.”

July 23, 1937—The National Cancer Institute Act, introduced by Congressman Warren G. Magnuson, was passed by Congress. An appropriation of \$700,000 for each fiscal year was authorized.

July 1, 1944—The Public Health Service Act, Public Law 410, 78th Congress provided that “The National Cancer Institute shall be a division in the National Institutes of Health.” The act also revised and consolidated many revisions into a single law. The limit of \$700,000 annual appropriation was removed.

December 4, 1970—Senator Ralph Yarborough, Texas, introduced S. 4564, “A bill which would establish a National Cancer Authority for the purpose of devising and implementing a national program for the conquest of the world’s most dreaded disease—cancer.”

January 22, 1971—In his State of the Union Message, President Nixon announced that he would ask for the appropriation of an additional \$100 million to launch an intensive effort to control cancer, and that he would ask later for whatever additional funds could be effectively used.

October 18, 1971—The President announced that the Army’s Biological Defense Research Center at Fort Detrick, Maryland would be converted into a leading center for cancer research as part of the major campaign to conquer cancer.

December 7, 1971—After three conference sessions that began on November 30, the Senate-House Conference Committee agreed on an expanded cancer program.

December 23, 1971—The President signed P. L. 92-218, The National Cancer Act of 1971, providing increased authorities and responsibilities for the NCI Director; initiating a National Cancer Program; establishing a three-member

President’s Cancer Panel and a 23-member National Cancer Advisory Board; establishing cancer control programs as necessary for cooperation with State and other health agencies, and providing for the collection, analysis, and dissemination of all data useful in the diagnosis, prevention, and treatment of cancer, including the establishment of an international cancer research data bank.

January-February 1974—Hearings were held on the proposed legislation to improve on the National Cancer Plan and to authorize appropriations for the next three years.

July 23, 1974—The National Cancer Act Amendments of 1974, P.L. 93-352, was signed. The Amendments: encourage the NCP to explore the role of nutrition in the treatment, rehabilitation, and causation of cancer; authorize the Director to include personnel needs in the budget estimate to OMB; remove the limit on the number of comprehensive cancer centers; increase the number of expert appointments to 100; and direct the NCI to provide and contract for a program to disseminate and interpret information respecting the cause, prevention, diagnosis and treatment of cancer.

August 1, 1977—The Biomedical Research Extension Act of 1977, P.L. 95-83, increased the number of expert appointments from 100 to 151.

November 9, 1978—The Biomedical Research and Training Amendments of 1978, P.L. 95-622, was signed into law. The amendments redefined the National Cancer Program to highlight prevention activities; expanded the membership of the National Cancer Advisory Board to 29 members, identifying a minimum of 5 to be knowledgeable in environmental and occupational carcinogenesis and 2 to be physicians primarily involved in treating cancer patients; added basic research to the cancer centers authority; authorized travel and moving expenses to and from duty station for experts; and emphasized education and information in all aspects of the National Cancer Program.

HISTORICAL EVENTS

- August 5, 1937**—President Franklin D. Roosevelt signed the National Cancer Act.
- November 9, 1937**—The National Advisory Cancer Council held its first meeting
- January 13, 1938**—Dr. Carl Voegtlin was appointed the first Director of the Institute.
- October 31, 1940**—President Franklin D. Roosevelt dedicated Building 6.
- July 1, 1947**—NCI reorganized to provide for expanded program; intramural cancer research, cancer research grants, and cancer control activities.
- July 2, 1953**—NCI inaugurated a full-scale clinical research program in the new Clinical Center.
- April 1955**—The Cancer Chemotherapy National Service Center was established in the Institute to coordinate the first national, voluntary, cooperative cancer chemotherapy program.
- January 11, 1966**—NCI reorganized to coordinate related activities. The areas of three Scientific Directors were established: Etiology; Chemotherapy; and a group of discipline-oriented laboratories and branches referred to as General Laboratories and Clinics.
- February 13, 1967**—A Cancer Research Center was established in Baltimore USPHS Hospital to conduct an integrated program of laboratory and clinical research on the therapy and management of cancer patients.
- April 27, 1970**—At the request of Senator Ralph W. Yarborough, Chairman of the Committee on Labor and Public Welfare, the Senate approved the establishment of the National Panel of Consultants on the Conquest of Cancer.
- October 18, 1971**—President Nixon converted the Army's former biological warfare facilities at Fort Detrick, Md., to research on the causes, treatment and prevention of cancer.
- December 23, 1971**—President Nixon signed P.L. 92-218, The National Cancer Act of 1971.
- June 22, 1972**—The Institute awarded a contract for the operation and maintenance of the Frederick Cancer Research Center at Fort Detrick, Maryland. This constituted the largest research contract ever awarded by a research component of the National Institutes of Health.
- June 30, 1972**—A team of five U. S. cancer scientists met with Russian scientists in Moscow to exchange information on cancer drugs. Dr. C. Gordon Zubrod, Scientific Director for Chemotherapy, NCI, on behalf of the United States, signed a U.S.-U.S.S.R. agreement on the exchange of drugs, visiting scientists, and information.
- July 27, 1972**—A Bureau-level organization was established for the National Cancer Institute, giving the Institute and its components organizational status commensurate with the responsibilities bestowed on it by The National Cancer Act of 1971. Under the reorganization, the Institute was composed of the Office of the Director and four Divisions: the Division of Cancer Biology and Diagnosis; Division of Cancer Cause and Prevention; Division of Cancer Treatment; and Division of Cancer Grants.
- September 10, 1974**—NCI established the Division of Cancer Control and Rehabilitation, which will plan, direct and coordinate an integrated program of activities regarding the widespread application of available and new methods for reducing the incidence, morbidity and mortality from cancer.
- July 1975**—The Division of Cancer Treatment was expanded to include the NCI Surgery and Radiation Oncology Branches and the extramural program of Cancer Cooperative Clinical Trials. The reorganization strengthened the Division's capabilities for conducting a national program of research on cancer treatment by combined modalities.
- May 15, 1978**—The first phase of an extensive NCI reorganization was announced. Day-by-day administrative and funding responsibility for extramural research programs was consolidated in each of the four research divisions. Responsibility for grant and contract review committees and for other committee management activities was transferred to the Division of Cancer Research Resources and Centers.
- July 18, 1979**—NCI and the National Naval Medical Center entered into an agreement to cooperate in a research program in cancer treatment at the Naval Medical facility.
-

**DIRECTOR
NATIONAL CANCER PROGRAM
NATIONAL CANCER INSTITUTE**

Vincent T. DeVita, Jr., M.D.

January 1, 1980 TO PRESENT

Dr. Vincent T. DeVita, Jr., received his B.S. degree in 1957 from the College of William and Mary and in 1961 received his M.D. degree with distinction from the George Washington School of Medicine. He interned at the University of Michigan Medical Center and then completed a year of residency with the George Washington University medical service. Dr. DeVita joined NCI in 1963 as a clinical associate, and after completing a senior residency at the Yale-New Haven Medical Center in 1965-66, returned to NCI as a senior investigator in the Solid Tumor Service and, in 1971, became Chief of the Medicine Branch. He was

named Director of the Division of Cancer Treatment in 1974 and, in 1975, Clinical Director of the Institute. In January 1980 he was appointed Acting Director, National Cancer Institute. Dr. DeVita serves on the editorial boards of numerous medical journals, maintains memberships in many scientific societies, and was President of the American Society of Clinical Oncology (1977-78). For his outstanding research and medical leadership, he has received a number of honors and awards, including the 1972 Albert and Mary Lasker Medical Research Award.

PRESIDENT'S CANCER PANEL

| | EXPIRATION OF APPOINTMENT |
|---|---------------------------------|
| Dr. Joshua Lederberg, <i>Chairman</i> Rockefeller University New York, New York | 1981 |
| Dr. Elizabeth C. Miller McArdle Laboratory for Cancer Research Madison, Wisconsin | 1980 |
| Dr. Bernard Fisher University of Pittsburgh Pittsburgh, Pennsylvania | 1982 |

NATIONAL CANCER INSTITUTE EXECUTIVE COMMITTEE

Dr. Vincent T. DeVita, Jr., *Chairman*
Acting Director, National Cancer Institute

Mr. Calvin B. Baldwin, Jr.
Associate Director for Administrative Management

Mr. Louis M. Carrese
Associate Director for Program Planning and Analysis

Dr. Diane J. Fink
Acting Associate Director for Medical Applications of
Cancer Research

Dr. Thomas J. King
Director, Division of Research Resources and Centers

Dr. Robert W. Miller
Acting Associate Director for International Affairs

Dr. Bayard H. Morrison III
Assistant Director, NCI

Dr. Gregory T. O'Connor
Director, Division of Cancer Cause and Prevention

Dr. Alan S. Rabson
Director, Division of Cancer Biology and Diagnosis

Dr. Saul A. Schepartz
Acting Director, Division of Cancer Treatment

Dr. William D. Terry
Acting Director, Division of Cancer Control and Rehabilitation

Dr. Richard A. Tjalma
Assistant Director, NCI

Mr. J. Paul Van Nevel
Associate Director for Cancer Communications

NATIONAL CANCER ADVISORY BOARD

APPOINTEES

| | EXPIRATION OF APPOINTMENT | | EXPIRATION OF APPOINTMENT |
|--|---------------------------|--|---------------------------|
| Dr. Henry C. Pitot, <i>Chairman</i> University of Wisconsin Madison, Wisconsin | 1982 | Dr. William E. Powers Harper Grace Hospital Detroit, Michigan | 1980 |
| Dr. Bruce N. Ames University of California Berkeley, California | 1982 | Dr. Janet D. Rowley University of Chicago Chicago, Illinois | 1984 |
| Dr. Harold Amos Harvard Medical School Boston, Massachusetts | 1982 | Mr. Sheldon W. Samuels AFL-CIO Washington, D. C. | 1984 |
| Dr. William O. Baker Bell Telephone Laboratories, Inc. Murray Hill, New Jersey | 1980 | Mr. Morris M. Schrier MCA, Inc. Scarsdale, New York | 1984 |
| Dr. G. Denman Hammond University of Southern California Los Angeles, California | 1980 | Dr. Irving J. Selikoff Mount Sinai School of Medicine New York, New York | 1984 |
| Dr. Maureen A. Henderson University of Washington Seattle, Washington | 1984 | Dr. Frederick Seitz The Rockefeller University New York, New York | 1982 |
| Mrs. Albert D. Lasker Albert and Mary Lasker Foundation New York, New York 10017 | 1980 | Dr. William W. Shingleton Duke University Medical Center Durham, North Carolina | 1980 |
| Mrs. Vincent Lombardi Manalapan, Florida | 1982 | Dr. Philippe Shubik German Cancer Center German Federal Republic | 1982 |
| Dr. Joseph H. Ogura Washington University St. Louis, Missouri | 1980 | Dr. Gerald N. Wogan Massachusetts Institute of Technology Cambridge, Massachusetts | 1984 |

EX OFFICIO MEMBERS

| | |
|---|--|
| Dr. John H. Moxley, III Assistant Secretary of Defense Washington, D. C. | Dr. Jere Edwin Goyan Food and Drug Administration Rockville, Maryland |
| Dr. Frank Press Office of Science and Technology Policy Washington, D. C. | Dr. Anthony Robbins National Institute for Occupational Safety and Health Rockville, Maryland |
| Mr. Douglas Costle Environmental Protection Agency Washington, D. C. | Dr. David P. Rall National Institute of Environmental Health Sciences Research Triangle Park, North Carolina |
| Ms. Susan B. King Consumer Product Safety Commission Washington, D. C. | Mrs. Patricia R. Harris Secretary of Health, Education, and Welfare Washington, D. C. |
| The Honorable Ray Marshall Secretary of Labor Washington, D. C. | Dr. Donald S. Fredrickson Director, National Institutes of Health, PHS Bethesda, Maryland |
| Dr. James Crutcher Veterans Administration Washington, D. C. | |


ALTERNATES

| | |
|---|--|
| Dr. F. Kash Mostofi Chairman, Armed Forces Institute of Pathology Washington, D. C. | Mr. Anson M. Keller U. S. Department of Labor Washington, D. C. |
| Dr. Gilbert S. Omenn Office of Science and Technology Policy Washington, D. C. | Dr. Joseph Rodricks Food and Drug Administration Rockville, Maryland |
| Dr. Richard E. Marland Environmental Protection Agency Washington, D. C. | |
| Dr. Marguerite T. Hays Veterans Administration Washington, D. C. | |
| Dr. Joseph McLaughlin Consumer Product Safety Commission Washington, D. C. | |

EXECUTIVE SECRETARY

| |
|--|
| Dr. Thomas J. King Director, Division of Cancer Research Resources and Centers National Cancer Institute, NIH Bethesda, Maryland |
|--|

NATIONAL CANCER INSTITUTE



OFFICE OF THE DIRECTOR

Dr. Vincent T. DeVita, Jr.
Acting Director

Plans, develops, directs, and coordinates the activities and programs of the Institute and of the National Cancer Program; and provides overall administrative guidance and services.

**OFFICE OF PROGRAM
PLANNING AND ANALYSIS**

Mr. Louis M. Carrese

Manages development of the National Cancer Program Plan, the annual 5-year plan, individual program plans, and the evaluation plan; analyzes programs of the Institute; evaluates resource needs for the National Cancer Program; develops and provides support for management and scientific information systems.

**PROGRAM ANALYSIS AND
FORMULATION
BRANCH**
Mr. Louis M. Carrese (acting)

**SYSTEMS PLANNING
BRANCH**
Ms. Barbara Murray (acting)

**OFFICE OF
CANCER COMMUNICATIONS**

Mr. J. Paul Van Nevel

Develops and manages the program communications activities of the NCI/NCP; interprets program and organizes, prepares and disseminates reports on cancer research for research institutions and other organizations participating in the NCP; maintains liaison with NCI constituents on behalf of the Director; responds to public inquiries; prepares and coordinates internal reports for dissemination within the Institute, the Executive Branch, and the Congress; and serves as a focal point for information on legislation.

**INFORMATION RESOURCES
BRANCH**
Mr. J. Paul Van Nevel (acting)

**REPORTS AND INQUIRIES
BRANCH**
Dr. Robert M. Hadsell (acting)

**INFORMATION PROJECTS
BRANCH**
Ms. Elaine Bratic

**OFFICE OF
INTERNATIONAL AFFAIRS**

Dr. Robert W. Miller (acting)

Plans, coordinates, and manages cooperative international cancer research activities and provides leadership within the National Cancer Institute for the development of international programs and activities.

**OFFICE OF
ADMINISTRATIVE MANAGEMENT**

Mr. Calvin B. Baldwin, Jr.
Executive Officer
Mr. Robert M. Namovicz
Deputy Executive Officer

Directs, coordinates, and conducts administrative management activities of the Institute including: personnel, budget, contracts, and administrative services; advises Director on administrative management aspects of the program.

**ADMINISTRATIVE
SERVICES
BRANCH**
Mr. Thomas L. Kearns

**FINANCIAL MANAGEMENT
BRANCH**
Mr. John P. Hartinger

**PERSONNEL MANAGEMENT
BRANCH**
Mrs. Elizabeth Stroud

**RESEARCH CONTRACTS
BRANCH**
Mr. James E. Graalman

**MANAGEMENT POLICY
BRANCH**
Mr. Paul H. Schaffer (acting)

DIVISION OF CANCER CAUSE AND PREVENTION
 Dr. Gregory T. O'Connor, Director

Plans and directs a program of laboratory, field and demographic research on the cause and natural history of cancer and means for preventing cancer through direct in-house research and through research contracts; evaluates mechanisms of cancer induction by viruses and by environmental carcinogenic hazards; serves as the focal point for the Federal Government on the synthesis of clinical, epidemiological, and experimental data relating to the cause of cancer; and participates in the evaluation of and advises the Institute Director on program-related aspects of cancer control activities and of grants and grant applications as they relate to cancer cause and prevention.

BOARD OF SCIENTIFIC COUNSELORS

BIOLOGICAL CARCINOGENESIS BRANCH
 Dr. James T. Duff

CHEMICAL AND PHYSICAL CARCINOGENESIS BRANCH
 Dr. Thaddeus Domanski

SPECIAL PROGRAMS BRANCH
 Dr. Donald Luecke

ADMINISTRATIVE MANAGEMENT BRANCH
 Mr. John M. Miller

FIELD STUDIES AND STATISTICS PROGRAM
 Dr. Joseph F. Fraumeni (acting)

Plans, conducts, and evaluates demographic research activities of the NCP and provides statistical services for all NCP research programs.

BIOMETRY BRANCH
 Dr. Earl S. Pollack

ENVIRONMENTAL EPIDEMIOLOGY BRANCH
 Dr. Joseph F. Fraumeni, Jr.

CLINICAL EPIDEMIOLOGY BRANCH
 Dr. Robert W. Miller

CARCINOGENESIS RESEARCH PROGRAM
 Vacant

Plans, directs, and conducts a basic and applied research program on the role of chemical and physical causative factors and the prevention of carcinogenesis; conducts programs in the areas of carcinogenesis and related toxicology, metabolism, chemistry, cell biology, and experimental tumor pathology.

LABORATORY OF BIOLOGY
 Dr. Joseph A. DiPaolo

LABORATORY OF MOLECULAR CARCINOGENESIS
 Dr. Harry V. Gelboin

LABORATORY OF EXPERIMENTAL PATHOLOGY
 Dr. Umberto Saffiotti

LABORATORY OF CHEMOPREVENTION
 Dr. Michael B. Sporn

LABORATORY OF CARCINOGEN METABOLISM
 Dr. Elizabeth K. Weisburger

CARCINOGENESIS TESTING PROGRAM
 Dr. Richard A. Griesemer

Plans, directs, and conducts a program for the in vivo and in vitro testing of chemical and physical agents in the environment for carcinogenic and cocarcinogenic effects; conducts programs in the development and evaluation of standardized methods, designs and models for in vivo and in vitro carcinogenesis testing, related toxicology, and tumor pathology.

TECHNICAL INFORMATION RESOURCES BRANCH
 Dr. Kenneth Chu

TOXICOLOGY BRANCH
 Dr. Thomas E. Hamm, Jr. (acting)

TUMOR PATHOLOGY BRANCH
 Dr. Richard A. Griesemer (acting)

VIRAL ONCOLOGY PROGRAM
 Dr. Louis R. Sibal (acting)


Plans and conducts the Institute's program of research and development dealing with viruses as etiological agents of cancer; supports programmatic investigations aimed at the detection, propagation, characterization, prevention, and control of tumor viruses and/or their induced diseases.


LABORATORY OF TUMOR VIRUS GENETICS
 Dr. Edward M. Scolnick

LABORATORY OF CELLULAR AND MOLECULAR BIOLOGY
 Dr. Stuart A. Aaronson

LABORATORY OF MOLECULAR VIROLOGY
 Dr. Robert A. Manaker

LABORATORY OF VIRAL CARCINOGENESIS
 Dr. George J. Todaro





BOARD OF SCIENTIFIC COUNSELORS

DIVISION OF CANCER TREATMENT
 Dr. Saul A. Schepartz, Acting Director
 Dr. Vincent T. DeVita, Jr., Clinical Director Dr. John L. Ziegler, Deputy Clinical Director
 Dr. Abraham Goldin, Assistant Director for International Treatment Research

Plans, directs and coordinates an integrated program of cancer treatment activities with the objective of curing or controlling cancer in man by utilizing combination modalities including chemical, surgical, radiological and certain immunological techniques; administers a total drug development program; and serves as the national focal point for information and data on cancer treatment studies.

ADMINISTRATIVE MANAGEMENT AND PLANNING BRANCH
 Mr. Michael Goldrich (acting)

CANCER THERAPY EVALUATION PROGRAM
 Dr. John S. MacDonald

Plans and directs the clinical contract and grant programs, testing combined modality therapy approaches and the testing of investigational new agents; and directs the evaluation of the effectiveness of specific types and methods of cancer therapy.

CLINICAL ONCOLOGY PROGRAM
 Dr. John L. Ziegler

Plans and directs the clinical research aspects of the programs of the Division.

DEVELOPMENTAL THERAPEUTICS PROGRAM
 Dr. Vincent T. Oliverio

Plans, directs, conducts and evaluates intramural and extramural research programs directed toward the preclinical development of therapeutic modalities, especially those related to chemotherapy.

BALTIMORE CANCER RESEARCH PROGRAM
 Dr. Peter H. Wiernik (acting)

Conducts an integrated program of laboratory and clinical research on the therapy and management of cancer patients, including pharmacologic investigations of the mechanisms of action of anticancer drugs.

INVESTIGATIONAL DRUG BRANCH
 Dr. Vincent H. Bono, Jr.

CLINICAL INVESTIGATIONS BRANCH
 Dr. Raymond Weiss

CLINICAL PROJECTS BRANCH
 Dr. Roger Halterman

RADIOTHERAPY DEVELOPMENT BRANCH
 Dr. David A. Pistenma

MEDICINE BRANCH
 Dr. Robert C. Young

PEDIATRIC ONCOLOGY BRANCH
 Dr. Arthur S. Levine

NCI-VA MEDICAL ONCOLOGY BRANCH
 Dr. John D. Minna

SURGERY BRANCH
 Dr. Steven A. Rosenberg

RADIATION ONCOLOGY BRANCH
 Dr. Eli J. Glatstein

CLINICAL PHARMACOLOGY BRANCH
 Dr. Bruce A. Chabner

BIOMETRIC RESEARCH BRANCH
 Dr. Richard Simon

LABORATORY OF CHEMICAL PHARMACOLOGY
 Dr. Richard H. Adamson

LABORATORY OF TOXICOLOGY
 Dr. Anthony M. Guarino

LABORATORY OF MOLECULAR PHARMACOLOGY
 Dr. Kurt W. Kohn

LABORATORY OF TUMOR CELL BIOLOGY
 Dr. Robert C. Gallo

EXPERIMENTAL THERAPEUTICS BRANCH
 Vacant

DRUG SYNTHESIS AND CHEMISTRY BRANCH
 Dr. Ven Narayanan (acting)

DRUG EVALUATION BRANCH
 Dr. John M. Venditti

PHARMACEUTICAL RESOURCES BRANCH
 Dr. J. Paul Davignon

LABORATORY OF MEDICINAL CHEMISTRY AND BIOLOGY
 Dr. David G. Johns

NATURAL PRODUCTS BRANCH
 Dr. John D. Douros

CLINICAL ONCOLOGY BRANCH
 * Dr. Peter H. Wiernik

LABORATORY OF CLINICAL BIOCHEMISTRY
 Dr. Nicholas R. Bachur

LABORATORY OF MOLECULAR BIOLOGY
 Dr. Carl C. Levy

DIVISION OF CANCER RESEARCH RESOURCES AND CENTERS
Dr. Thomas J. King, Director
Dr. William A. Walter, Deputy Director

Plans and directs the Institute's grant-supported activities; recommends Institute policies relating to the administration of grant programs; develops, reviews and coordinates plans and criteria for the implementation of NCI grants and evaluates effectiveness of grant-supported activities in achieving the Institute's missions; and advises the Institute Director, the National Cancer Advisory Board, and other advisory bodies of grant activities and developments.

BIOLOGICAL RESEARCH PROGRAM
Vacant

Plans and directs NCI grant-supported activities, and recommends Institute policies relating to the administration of biomedical and clinical research grant programs; develops, reviews and coordinates plans and criteria for the implementation of NCI grant-supported, research programs and evaluates effectiveness of these activities in achieving the Institute's missions; and advises the Director of the Division, the National Cancer Advisory Board, and other scientific advisory bodies of activities and developments.

ORGAN SITE PROGRAMS BRANCH
Dr. Samuel Price

GRANTS ADMINISTRATION BRANCH
Mr. Leo F. Buscher, Jr.

RESEARCH ANALYSIS AND EVALUATION BRANCH
Mr. Harry Y. Canter

GRANTS FINANCIAL AND DATA ANALYSIS BRANCH
Mr. Robert E. Spallone

CONTRACTS REVIEW BRANCH
Dr. David L. Joffes (acting)

GRANTS REVIEW BRANCH
Dr. David L. Joffes

TRAINING AND EDUCATION PROGRAM
Vacant

Plans, directs and manages the Fellowships Programs, the Research Career Development Awards Program, the Research Training Program and the Clinical Education Program; develops, reviews and coordinates plans and criteria for the implementation of these programs and evaluates effectiveness of these activities; and advises the Director of the Division, the National Cancer Advisory Board, and other scientific advisory bodies of activities and developments.

RESEARCH MANPOWER BRANCH
Dr. Barney C. Lepovetsky

CLINICAL MANPOWER BRANCH
Dr. Margaret H. Edwards

CENTERS AND TREATMENT PROGRAM
Dr. William D. Terry (Acting Director)

Plans and directs the Cancer Centers Program, the Research Facilities Construction Program, and the Diagnosis and Treatment Program; supplies data to review committees and the National Cancer Advisory Board; evaluates the need for and effectiveness of these programs; interprets programs to grant applicants, grantees, universities and research institutions; and advises the Director of the Division, the National Cancer Advisory Board and other advisory bodies of grants activities and developments.

CANCER CENTERS BRANCH
Dr. William L. Roberson

RESEARCH FACILITIES BRANCH
Dr. Donald G. Fox

DIVISION OF CANCER CONTROL AND REHABILITATION
Dr. William D. Terry, Acting Director

Plans, directs, and coordinates an integrated program of cancer control and rehabilitation activities with the goal of identifying, testing, evaluating, demonstrating, communicating and promoting the widespread application of available and new methods for reducing the incidence, morbidity, and mortality from cancer; serves as the focal point of a coordinated national effort to control cancer; in collaboration with the research divisions of the National Cancer Institute, identifies candidate control techniques and methods for inclusion in the field test and demonstration activities of the division; and advises the Institute Director on program related aspects of grants and contracts.

OFFICE OF PLANNING AND ANALYSIS
Clifford Noyes (acting)

INTERVENTION PROGRAMS
Vacant

Assists in the development of the national program plan for cancer control; plans and directs a program to identify, field test and evaluate discrete or individual intervention methods and techniques; coordinates program activities with other NCI components and non-NCI organizations supporting or performing related activities; and advises the Director, DCCR, on the needs, status and progress of the activities involving the development of individual intervention tools.

COMMUNITY PROGRAMS
Vacant

Assists in the development of the national program plan for cancer control; plans and directs a program to demonstrate and promote available, effective and practical cancer control intervention techniques and monitors and evaluates the effectiveness of community demonstration activities in achieving the desired results; coordinates program activities with other NCI components and non-NCI organizations supporting or performing related activities; and advises the Director, DCCR, on the needs, status and progress of the activities involving community demonstration of proven methods and techniques of cancer control.


TREATMENT, REHABILITATION AND CONTINUING CARE BRANCH
Ms. Janet L. Lunceford (acting)

PREVENTIVE MEDICINE BRANCH
Dr. Richard Costlow

COMMUNITY SPECIAL PROJECTS BRANCH
Dr. Veronica Conley

TOTAL NATIONAL RESOURCES FOR CANCER RESEARCH AND CANCER CONTROL – FISCAL YEAR 1979

TOTAL: \$1,580,872,000



NCI portion represents actual 1979 obligations. Non-NCI portions were provided by a study sponsored by the Office of Program Planning and Analysis, NCI.

NATIONAL CANCER PROGRAM STRATEGY

The essential and continuing goal of the National Cancer Institute (NCI) is the same today as it was when the Institute was created by an Act of Congress 40 years ago: To develop the means for reducing the incidence, morbidity, and mortality of cancer. The NCI continues to be the lead federal agency in cancer, responsible and accountable for the investment of progress toward that goal. However, the National Cancer Act of 1971 (amended in 1974 and 1978) brought about some changes which have had significant impact on cancer research. The most obvious impact has been that the level of support for cancer research and control activities with public funds has increased four-fold since 1971. But the mandate from Congress to intensify and expand the cancer effort has had other implications beyond the increase of resources for the National Cancer Program.

The 1978 amendment to the 1971 Cancer Act redefined the National Cancer Program (NCP) and stated that "The National Cancer Program shall consist of (1) an expanded, intensified, and coordinated cancer research program encompassing the research programs conducted and supported by the Institute and the related research programs of the other research institutes and including an expanded and intensified research program for the prevention of cancer caused by occupational or environmental exposure to carcinogens, and (2) the other programs and activities of the Institute." Thus, the Act not only provided the public with both a symbolic and operational entity with which to identify at the national level, but also brought about a greater spirit and degree of awareness, cooperation, and coordination among federal programs.

The National Cancer Program has three major program components:

- Research
- Control
- Support.

The first two components encompass the scientific and technical activities, while the support component includes those activities needed to carry out the research and control efforts effectively (e.g., construction and manpower development activities).


The addition of cancer control responsibilities to NCI's research responsibilities and through the specific emphasis placed on the expansion of comprehensive cancer centers as focal points for research, teaching, and demonstration, served to further emphasize the axiom that the ultimate purpose of disease research is to produce results that can be translated into improved methods for the prevention and treatment of disease in people, and that the National Cancer Program would invest significant effort and resources in this area.

One important characteristic of the NCP since its inception has been the extensive and continuous participation of the biomedical community in the major planning efforts of the NCI. Beginning with the development of the first edition of the National Cancer Program Plan in 1972, periodic planning sessions have been held for the purpose of revising and updating the major recommendations for research and control activities.

The general character of the Program has become increasingly the product of a more extensive and frequent interaction among Congress, the public, the biomedical community, and federal agencies. In particular, the consistent and active roles of the President's Cancer Panel and the National Cancer Advisory Board have established a model for effective and productive relationships between national advisory committees and the federal agency.

NATIONAL CANCER INSTITUTE ACTUAL vs. CONSTANT DOLLAR FUNDING

(MILLIONS OF DOLLARS)



NUMBER OF DEATHS FOR THE FIVE LEADING CANCER SITES BY AGE GROUP AND SEX—1977

| TOTAL | | UNDER 15 | | 15-34 | | 35-54 | | 55-74 | | 75+ | |
|-------------------------------------|-------------------------------------|----------------------------------|-------------------------|--------------------------|--------------------------|-------------------------|-------------------------|--------------------------|--------------------------|-------------------------|--------------------------|
| MALE | FEMALE | MALE | FEMALE | MALE | FEMALE | MALE | FEMALE | MALE | FEMALE | MALE | FEMALE |
| Lung 68,362 | Breast 34,478 | Leukemia 633 | Leukemia 422 | Leukemia 755 | Breast 623 | Lung 10,110 | Breast 8,348 | Lung 44,112 | Breast 17,341 | Lung 14,060 | Colon & Rectum 11,953 |
| Colon & Rectum 24,956 | Colon & Rectum 26,574 | Brain & CNS 414 | Brain & CNS 302 | Brain & CNS 474 | Leukemia 553 | Colon & Rectum 2,434 | Lung 4,528 | Colon & Rectum 13,504 | Lung 13,045 | Prostate 11,645 | Breast 8,166 |
| Prostate 20,789 | Lung 21,974 | Bone 58 | Bone 47 | Testis 423 | Brain & CNS 316 | Pancreas 1,307 | Colon & Rectum 2,283 | Prostate 8,851 | Colon & Rectum 12,190 | Colon & Rectum 8,811 | Lung 4,341 |
| Pancreas 10,938 | Uterus 10,906 | Connective Tissue 50 | Connective Tissue 46 | Hodgkin's Disease 352 | Uterus 303 | Brain & CNS 1,200 | Uterus 2,093 | Pancreas 6,378 | Ovary 6,000 | Pancreas 3,205 | Pancreas 3,778 |
| Stomach 8,687 | Ovary 10,494 | Lympho- & Reticulo sarcoma 49 | Kidney 35 | Skin 254 | Hodgkin's Disease 235 | Leukemia 1,046 | Ovary 2,063 | Stomach 4,652 | Uterus 5,573 | Bladder 3,121 | Uterus 2,970 |

SOURCE: Vital Statistics of the United States, 1977.

RELATIONSHIP OF CANCER TO LEADING CAUSES OF DEATH IN THE UNITED STATES—1977

| RANK | CAUSE OF DEATH | NUMBER OF DEATHS | DEATH RATE PER 100,000 POPULATION | PERCENT OF TOTAL DEATHS |
|------|-------------------------|------------------|-----------------------------------|-------------------------|
| | All Causes | 1,899,597 | 878.1 | 100.0 |
| 1 | Diseases of Heart | 718,850 | 332.3 | 37.8 |
| 2 | Cancer | 386,686 | 178.7 | 20.4 |
| 3 | Stroke | 181,934 | 84.1 | 9.6 |
| 4 | Accidents | 103,202 | 47.7 | 5.4 |
| 5 | Influenza and Pneumonia | 51,193 | 23.7 | 2.7 |
| 6 | Diabetes Mellitus | 32,989 | 15.2 | 1.7 |
| 7 | Cirrhosis of Liver | 30,848 | 14.3 | 1.6 |
| 8 | Arteriosclerosis | 28,754 | 13.3 | 1.5 |
| 9 | Suicide | 28,681 | 13.3 | 1.5 |
| 10 | Diseases of Infancy | 23,401 | 10.8 | 1.2 |
| 11 | Homicide | 19,968 | 9.2 | 1.1 |
| 12 | Emphysema | 16,376 | 7.6 | 0.9 |
| 13 | Congenital Anomalies | 12,983 | 6.0 | 0.7 |
| 14 | Nephritis and Nephrosis | 8,519 | 3.9 | 0.5 |
| 15 | Septicemia and Pyemia | 7,112 | 3.3 | 0.4 |
| | Other and Ill-Defined | 248,101 | 114.7 | 13.1 |

SOURCE: Vital Statistics of the United States, 1977.

ESTIMATED CANCER DEATHS AND NEW CASES BY SEX AND SITE — 1980¹

| SITE | ESTIMATED DEATHS | | | ESTIMATED NEW CASES | | |
|---|--------------------|---------|---------|----------------------|----------------------|----------------------|
| | TOTAL | MALE | FEMALE | TOTAL | MALE | FEMALE |
| All Sites | 405,000 | 219,500 | 185,500 | 785,000 ¹ | 387,000 ¹ | 398,000 ¹ |
| Buccal Cavity & Pharynx (Oral) | 8,800 | 6,100 | 2,700 | 25,500 | 17,900 | 7,600 |
| Lip | 175 | 150 | 25 | 4,400 | 4,000 | 400 |
| Tongue | 2,000 | 1,400 | 600 | 4,800 | 3,200 | 1,600 |
| Salivary Gland | 650 | 400 | 250 | | | |
| Floor of Mouth | 525 | 400 | 125 | 9,300 | 5,600 | 3,700 |
| Other & Unspecified Mouth | 1,450 | 950 | 500 | | | |
| Pharynx | 4,000 | 2,800 | 1,200 | 7,000 | 5,100 | 1,900 |
| Digestive Organs | 106,850 | 55,900 | 50,950 | 186,300 | 95,800 | 90,500 |
| Esophagus | 7,600 | 5,500 | 2,100 | 8,800 | 6,200 | 2,600 |
| Stomach | 14,000 | 8,400 | 5,600 | 23,000 | 14,000 | 9,000 |
| Small Intestine | 700 | 350 | 350 | 2,200 | 1,200 | 1,000 |
| Large Intestine (Colon- Rectum Rectum) | 44,000 | 20,500 | 23,500 | 79,000 | 36,000 | 43,000 |
| Liver & Biliary Passages | 8,800 | 4,800 | 4,000 | 35,000 | 19,000 | 16,000 |
| Pancreas | 9,300 | 4,500 | 4,800 | 11,600 | 5,600 | 6,000 |
| Other & Unspecified Digestive | 20,900 | 11,100 | 9,800 | 24,000 | 12,500 | 11,500 |
| Other & Unspecified Digestive | 1,550 | 750 | 800 | 2,700 | 1,300 | 1,400 |
| Respiratory System | 106,200 | 78,600 | 27,600 | 130,700 | 96,000 | 34,700 |
| Larynx | 3,500 | 2,900 | 600 | 10,700 | 9,000 | 1,700 |
| Lung | 101,300 | 74,800 | 26,500 | 117,000 | 85,000 | 32,000 |
| Other & Unspecified Respiratory | 1,400 | 900 | 500 | 3,000 | 2,000 | 1,000 |
| Bone, Tissue & Skin | 9,550 | 5,400 | 4,150 | 20,500 | 10,500 | 10,000 |
| Bone | 1,750 | 1,000 | 750 | 1,900 | 1,100 | 800 |
| Connective Tissue | 1,600 | 800 | 800 | 4,500 | 2,500 | 2,000 |
| Skin | 6,200 ⁴ | 3,600 | 2,600 | 14,100 ² | 6,900 ² | 7,200 ² |
| Breast | 35,800 | 300 | 35,500 | 108,900 | 900 | 108,000 |
| Genital Organs | 45,300 | 22,500 | 22,800 | 146,500 | 71,000 | 75,500 |
| Cervix, Invasive Uterus | 7,400 | — | 7,400 | 16,000 ³ | — | 16,000 ³ |
| Corpus, Endometrium Uterus | 3,200 | — | 3,200 | 38,000 | — | 38,000 |
| Ovary | 11,200 | — | 11,200 | 17,000 | — | 17,000 |
| Prostate | 21,500 | 21,500 | — | 66,000 | 66,000 | — |
| Other & Unspecified Genital, Male | 1,000 | 1,000 | — | 5,000 | 5,000 | — |
| Other & Unspecified Genital, Female | 1,000 | — | 1,000 | 4,500 | — | 4,500 |
| Urinary Organs | 18,200 | 11,800 | 6,400 | 52,400 | 36,500 | 15,900 |
| Bladder | 10,300 | 7,000 | 3,300 | 35,500 | 26,000 | 9,500 |
| Kidney & Other Urinary | 7,900 | 4,800 | 3,100 | 16,900 | 10,500 | 6,400 |
| Eye | 400 | 200 | 200 | 1,800 | 900 | 900 |
| Brain & Central Nervous System | 9,800 | 5,400 | 4,400 | 11,900 | 6,600 | 5,300 |
| Endocrine Glands | 1,500 | 600 | 900 | 10,000 | 3,100 | 6,900 |
| Thyroid | 1,050 | 350 | 700 | 9,100 | 2,600 | 6,500 |
| Other Endocrine | 450 | 250 | 200 | 900 | 500 | 400 |
| Leukemia | 15,700 | 8,800 | 6,900 | 22,200 | 12,500 | 9,700 |
| Other Blood & Lymph Tissues | 20,700 | 10,800 | 9,900 | 39,200 | 20,800 | 18,400 |
| Hodgkin's Disease | 1,900 | 1,100 | 800 | 7,100 | 4,100 | 3,000 |
| Multiple Myeloma | 6,400 | 3,300 | 3,100 | 9,100 | 4,700 | 4,400 |
| Other Lymphomas | 12,400 | 6,400 | 6,000 | 23,000 | 12,000 | 11,000 |
| All Other & Unspecified Sites | 26,200 | 13,100 | 13,100 | 29,100 | 14,500 | 14,600 |

NOTE: The estimates of new cancer cases are offered as a rough guide and should not be regarded as definitive. Especially note that year-to-year changes may only represent improvements in the basic data.

¹ Carcinoma-in-situ and non-melanoma skin cancers not included in totals. Carcinoma-in-situ of the uterine cervix accounts for over 45,000 new cases annually. Non-melanoma skin cancer accounts for about 400,000 new cases annually. ² Melanoma only. ³ Invasive cancer only. ⁴ Melanoma 4,600; other skin, 1,600.

Incidence estimates are based on rates from NCI SEER Program, 1973-1976.

RESEARCH POSITIONS AT THE NATIONAL CANCER INSTITUTE¹

The National Cancer Institute recognizes that one of the most valuable resources to be drawn upon in the fight against cancer is the wealth of scientific talent available in the U. S. and around the world. In an effort to attract and maintain the highest quality scientific staff, two personnel systems are used: the U. S. Civil Service System and the PHS Commissioned Corps. In addition, the Staff Fellowship Program and the NIH Visiting Program have been designed to meet special needs. Special programs are also available for those who qualify.

| POSITION | ELIGIBILITY | ANNUAL SALARY | MECHANISM OF ENTRY |
|---|--|---|---|
| I. CIVIL SERVICE | | | |
| A. Civil Service (tenured) | Appropriate advanced education, experience and knowledge needed by NCI to conduct its programs. | Minimum starting: Ph.D. — \$29,375 Physicians — \$35,688 Maximum: \$50,113 | Office of Personnel Management, Contact Director or Laboratory Chief in area of interest or the NCI Personnel Office. |
| II. SPECIAL APPOINTMENT OF EXPERTS AND CONSULTANTS | | | |
| A. Special Appointment of Experts and Consultants (non-tenured appointment which can be extended up to 4 years. | Applicants shall possess outstanding experience and ability as to justify recognition as authorities in their particular fields of activity. | Equivalent to the salary range of GS-13 through GS-18. Maximum: \$50,113 | Recommendation by Division Directors. Final approval rests with the Director, NCI. |
| III. USPHS COMMISSIONED CORPS | | | |
| Associate Training including CORD residency deferment program (limited tenure, maximum 3 years) ² | | | |
| A. Clinical Associate | Graduates of Medical Schools including Internship. | Pay and allowances of Senior Assistant Surgeon or Surgeon of PHS Commissioned Corps. | Apply to Clinical and Professional Education Section, Clinical Center, National Institutes of Health 20205. |
| B. Research Associate | Graduates of Medical Schools including Internship. | Pay and allowances of Senior Assistant Surgeon or Surgeon of PHS Commissioned Corps. | ³ Apply to Clinical and Professional Education Section, Clinical Center, National Institutes of Health 20205. |
| C. Staff Associate | Graduates of medical and technical schools, or other doctoral qualifications. | Pay and allowances of Senior Assistant Surgeon of PHS Commissioned Corps. | Apply to Clinical and Professional Education Section, Clinical Center, National Institutes of Health 20205. |
| D. Senior COSTEP Program (Medical) | Senior Medical Students. | Pay and allowances of Junior Asst. Health Service Officer plus payment of tuition, fees and other necessary expenses. Candidates incur 2 year active duty obligation with PHS Commissioned Corps. | Apply to: Commissioned Personnel Operations Division, Parklawn Building, Room 4-35, 5600 Fishers Lane, Rockville, Maryland 20852. |
| IV. VISITING PROGRAM (limited tenure)⁴ | | | |
| A. Visiting Fellow (maximum 3 years) | 1-3 years postdoctoral experience or training. | Entrance stipend \$13,000-\$14,200 No dependency allowance provided. | Contact Director or Laboratory Chief in area of interest. |
| B. Visiting Associates (1 year with renewals to end of project) | 3+ years postdoctoral experience or training with appropriate knowledge needed by NCI. | \$17,035-\$32,110 | Contact Director or Laboratory Chief in area of interest. |
| C. Visiting Scientist (duration of project) | 6+ years postdoctoral experience with appropriate unusual experience and knowledge needed. | \$24,703-\$50,113 | Contact Director or Laboratory Chief in area of interest. |

V. STAFF FELLOWSHIPS

| POSITION | ELIGIBILITY | ANNUAL SALARY | MECHANISM OF ENTRY |
|----------------------------|---|---|---|
| A. Staff Fellowship | Physician or other doctoral degree equivalent awarded within last 5 years, U. S. citizen or non-citizen eligible for naturalization within 4 years. Maximum five-year appointment. | Staff Fellows Physicians \$19,740-\$29,541 Other Doctorates \$15,120-\$28,818 Senior Staff Fellows Physicians \$22,365-\$40,144 Other Doctorates \$19,740-\$32,312 | Contact Director or Laboratory Chief in area of interest or the NCI Personnel Office. |

VI. CIVIL SERVICE SUMMER EMPLOYMENT PROGRAMS

| | | | |
|---|--|--|---|
| A. Summer Employment Examination Program | Must be 18 years of age or older (16 if high school graduate). | GS-1 through GS-4 Grade is based on education and/or experience. | Must pass the Civil Service Summer Employment Examination. Apply to NIH between March 15 and April 16. |
| B. Summer Undergraduate Program | Students majoring in biological and/or physical sciences or related field, or applicants with appropriate experience. | GS-1 through GS-4 Grade is based on education and/or experience. | Apply to NIH by April 15. No written test is required. |
| C. Summer Graduate Program | College graduate, graduate student, planning to attend graduate school, faculty member, or equivalent experience and/or education. | GS-5 through GS-12 For some occupations superior scholastic work may qualify for a higher grade level. | Apply to NIH by March 17. |
| D. Summer Employment for Needy Youth | Educationally and economically disadvantaged youths in their formative years (must have reached 16th birthday). | Federal minimum wage. | Register with the local office of the State Employment service and apply to NIH. |
| E. Stay-in-School Program | Substantially full-time or full-time student at least 16 years of age who needs earnings from employment to continue in school. | Salary is commensurate with duties assigned and student's education and/or experience. | Apply to NIH. No deadline required for applying. However, no new appointments are made between May 1 to August 30. |
| F. The Federal Junior Fellowship Program | Graduating high school senior in a public or private school in the Metro. Wash., D. C. area. Must be in upper 10% of graduating class, have applied for admission to an accredited college or university and need financial assistance to attend school. | GS-1 through GS-4 | Nominations are submitted directly to the Office of Personnel Management by high school principals or counselors. |
| G. Federal Summer Intern Program | Undergraduate student who has completed 2 or more years and is in the upper 1/3 of class or graduate student in upper 1/2 of class. | GS-4 through GS-11 | Students should contact college placement office during month of February. NIH requests nominations from colleges that have expressed an interest in the program to the Office of Personnel Management. |


VII. SPECIAL PROGRAMS

| | | | |
|--|--|--|--|
| A. Research Fellow sponsored by organization other than NIH, PHS. | Determined by sponsoring organization. | Established by sponsoring organization. | Contact Director or Laboratory Chief in area of interest; also apply to sponsoring agency, e.g., American Cancer Society, Eleanor Roosevelt Cancer Foundation, Leukemia Society of America, Inc., etc. |
| B. COSTEP Program (operates year-round) Maximum 120 days per 12-month period. | U. S. Citizen. Must have completed one year of study in a medical, dental or veterinary school; or a minimum of two years of baccalaureate program in a health-related field such as engineering, nursing, pharmacy, etc. May be enrolled in a master's or doctoral program in a health-related field (designated by the Assistant Secretary for Health). Physical requirements of PHS Commissioned Corps. Plans to return to college. | Pay and allowance of a Commissioned Officer, Junior Asst. Grade. | Apply to PHS Commissioned Corps, COSTEP SECTION, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20852. |
| C. Fogarty International Scholars | International reputation, productivity, demonstrated ability in biomedical field. | \$40,000 per annum | Recommendation to Fogarty Center by Institute Director or Scientist. Contact Director in area of interest. |

¹ Does not necessarily indicate that positions are currently available at the National Cancer Institute.

² Appointments are made upon intellectual attainment and demonstrated research interest and ability matched to NCI's needs.

³ Under most circumstances, the various visiting programs are limited to non-citizens.



**BUILDING 10
CLINICAL CENTER**
87,800 Square Feet
420 Personnel

BUILDING 37
116,696 Square Feet
497 Personnel

BUILDING 13
1,641 Square Feet
10 Personnel

BUILDING 14
6,056 Square Feet
3 Personnel

WESTWOOD BUILDING
30,844 Square Feet
160 Personnel

Old Georgetown Road

Route 270

Route 495 (Capital Beltway)

Cedar Lane

North Drive

Center Drive

Wilson Dr.

South Drive

Lincoln Dr.

Service Road South

Center Drive

Old Georgetown Road

Delray Avenue

St. Elmo Avenue

Woodmont Ave.

Glenbrook Road

Arlington Road

Bradley Boulevard

WASHINGTON, D.C.

River Road

Ridgefield Road

Westbard Ave.

Little Falls Parkway

Dorset Avenue

Nicholson Lane

BUILDING 31
37,750 Square Feet
216 Personnel

BUILDING 8
12,563 Square Feet
40 Personnel

BUILDING 41
32,653 Square Feet
53 Personnel

DELRAY BUILDING
2,400 Square Feet
10 Personnel

LANDOW BUILDING
57,032 Square Feet
255 Personnel

***INCLUDED BUT NOT SHOWN**

FIELD STATIONS
59,485 Square Feet
121 Personnel


BLAIR BUILDING
8300 Colesville Road
Silver Spring, MD 20910
48,236 Square Feet
188 Personnel



BUILDING LOCATION AND SQUARE FOOTAGE OCCUPIED BY FULL-TIME PERMANENT PERSONNEL IN BETHESDA, MARYLAND AREA AS OF SEPTEMBER 30, 1979

TOTAL*
Approximately 493,156 Square Feet
1,973 Personnel

NCI BUDGET ADMINISTRATION PROCESS — UNDER CANCER ACT OF 1971



NOTE: SIMULTANEOUS ACTIVITIES BY MORE THAN ONE ORGANIZATION INDICATE COOPERATIVE EFFORTS

LEGEND: ● OPERATION ■ REVIEW ▲ DECISION

NATIONAL CANCER INSTITUTE BUDGET HISTORY BY MECHANISMS

(DOLLARS IN THOUSANDS)


| | 1971 ACTUAL | | 1972 ACTUAL | | 1973 ACTUAL | | 1974 ACTUAL | |
|---|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| | DOLLARS | PERCENT OF TOTAL | DOLLARS | PERCENT OF TOTAL | DOLLARS | PERCENT OF TOTAL | DOLLARS | PERCENT OF TOTAL |
| Group I – Investigator Initiated | | | | | | | | |
| Regular Research Grants | \$ 44,133 | 24.2 | \$ 59,207 | 18.9 | \$ 73,412 | 21.1 | \$ 99,415 | 21.5 |
| Clinical Cooperative Groups | 7,013 | 3.9 | 10,102 | 3.2 | 12,791 | 3.7 | 16,196 | 3.5 |
| Program Projects | 30,205 | 16.6 | 38,415 | 12.2 | 52,008 | 14.9 | 71,997 | 15.6 |
| Clinical Education Program | – | – | – | – | – | – | – | – |
| Research Career Program | 2,012 | 1.1 | 2,026 | 7 | 1,818 | 5 | 1,673 | 4 |
| Fellowships and Training | 12,560 | 6.9 | 18,395 | 5.9 | 13,888 | 4.0 | 23,562 | 5.1 |
| Organ Site | – | – | 638 | 2 | 3,950 | 1.1 | 10,007 | 2.2 |
| Cancer Centers – Core Support | 6,174 | 3.4 | 10,090 | 3.2 | 13,002 | 3.7 | 17,575 | 3.8 |
| Subtotal | 102,097 | 56.1 | 138,873 | 44.3 | 170,869 | 49.0 | 240,425 | 52.1 |
| Group II – Co-Initiated | | | | | | | | |
| Cancer Res. Emphasis Grants (CREG) | – | – | – | – | – | – | – | – |
| Research Contracts | 27,547 | 15.1 | 46,802 | 14.9 | 61,187 | 17.6 | 94,964 | 20.5 |
| Subtotal | 27,547 | 15.1 | 46,802 | 14.9 | 61,187 | 17.6 | 94,964 | 20.5 |
| Group III – NCI/NCP Initiated | | | | | | | | |
| Resource Contracts | 44,945 | 24.7 | 63,194 | 20.2 | 64,838 | 18.6 | 72,365 | 15.7 |
| Interagency Agreements | 5,704 | 3.1 | 12,053 | 3.8 | 10,136 | 2.9 | 13,031 | 2.8 |
| Subtotal | 50,649 | 27.8 | 75,247 | 24.0 | 74,974 | 21.5 | 85,396 | 18.5 |
| Group IV – Other Resources | | | | | | | | |
| Cancer Centers – Exploratory Grants | 1,889 | 1.0 | 1,698 | 5 | 2,500 | 7 | 2,880 | 6 |
| Construction Grants | – | – | 47,004 | 15.0 | 34,737 | 10.0 | 31,692 | 6.9 |
| Construction Contracts | – | – | 3,999 | 1.3 | 4,067 | 1.2 | 6,398 | 1.4 |
| Subtotal | 1,889 | 1.0 | 52,701 | 16.8 | 41,304 | 11.9 | 40,970 | 8.9 |
| Total | 182,182 | 100.0 | 313,623 | 100.0 | 348,334 | 100.0 | 461,755 | 100.0 |
| Percent of Total NCI Budget | | 80.3 | | 84.2 | | 81.9 | | 79.5 |
| In-House Research | 20,594 | 9.1 | 25,696 | 6.9 | 33,032 | 7.8 | 40,364 | 6.9 |
| Management & Support | 24,176 | 10.6 | 33,246 | 8.9 | 39,072 | 9.2 | 46,169 | 7.9 |
| (NIH Management Fund) | (10,917) | (4.8) | (12,910) | (3.5) | (15,194) | (3.6) | (16,754) | (2.9) |
| Cancer Control (Grants & Contracts) | – | – | – | – | 4,969 | 1.1 | 32,826 | 5.7 |
| Subtotal | 44,770 | 19.7 | 58,942 | 15.8 | 77,073 | 18.1 | 119,359 | 20.5 |
| Total NCI | \$226,952 | 100.0 | \$372,565 | 100.0 | \$425,407 | 100.0 | \$581,114 | 100.0 |

(SANDS)

| 1974 | 1975 ACTUAL | | 1976 ACTUAL | | 1977 ACTUAL | | 1978 ACTUAL | | 1979 ACTUAL | | |
|----------|------------------|-----------|------------------|-----------|------------------|-----------|------------------|-----------|------------------|-----------|------------------|
| DOLLARS | PERCENT OF TOTAL | DOLLARS | PERCENT OF TOTAL | DOLLARS | PERCENT OF TOTAL | DOLLARS | PERCENT OF TOTAL | DOLLARS | PERCENT OF TOTAL | DOLLARS | PERCENT OF TOTAL |
| 99,415 | 21.5 | \$115,195 | 21.4 | \$130,633 | 22.7 | \$140,159 | 23.0 | \$158,716 | 24.7 | \$188,488 | 27.3 |
| 16,196 | 3.5 | 19,213 | 3.6 | 23,263 | 4.0 | 27,121 | 4.5 | 29,774 | 4.6 | 32,021 | 4.6 |
| 71,997 | 15.6 | 84,536 | 15.7 | 80,029 | 13.9 | 83,453 | 13.7 | 88,058 | 13.7 | 93,953 | 13.6 |
| - | - | 5,033 | 9 | 7,698 | 1.3 | 8,996 | 1.5 | 9,952 | 1.5 | 11,404 | 1.7 |
| 1,673 | 4 | 2,806 | 5 | 3,243 | 6 | 3,507 | 6 | 4,399 | 7 | 4,771 | 0.7 |
| 23,562 | 5.1 | 23,104 | 4.3 | 18,160 | 3.1 | 19,791 | 3.3 | 20,129 | 3.1 | 20,139 | 2.9 |
| 10,007 | 2.2 | 11,167 | 2.1 | 14,090 | 2.5 | 14,711 | 2.4 | 16,194 | 2.5 | 17,032 | 2.5 |
| 17,575 | 3.8 | 30,096 | 5.6 | 47,803 | 8.3 | 55,132 | 9.1 | 60,348 | 9.4 | 64,364 | 9.3 |
| 240,425 | 52.1 | 291,150 | 54.1 | 324,919 | 56.4 | 352,870 | 58.1 | 387,570 | 60.2 | 432,172 | 62.6 |
| - | - | - | - | 2,577 | 5 | 7,266 | 1.2 | 9,412 | 1.5 | 7,894 | 1.1 |
| 94,964 | 20.5 | 105,076 | 19.5 | 111,524 | 19.3 | 110,740 | 18.2 | 120,359 | 18.6 | 81,119 | 11.8 |
| 94,964 | 20.5 | 105,076 | 19.5 | 114,101 | 19.8 | 118,006 | 19.4 | 129,771 | 20.1 | 89,013 | 12.9 |
| 72,365 | 15.7 | 82,916 | 15.4 | 96,509 | 16.7 | 94,229 | 15.5 | 87,806 | 13.6 | 130,161 | 18.9 |
| 13,031 | 2.8 | 11,593 | 2.2 | 13,262 | 2.3 | 19,414 | 3.2 | 21,621 | 3.4 | 20,734 | 3.0 |
| 85,396 | 18.5 | 94,509 | 17.6 | 109,771 | 19.0 | 113,643 | 18.7 | 109,427 | 17.0 | 150,895 | 21.9 |
| 2,880 | .6 | 2,568 | .4 | 2,803 | .5 | 1,199 | .2 | 632 | .1 | 271 | 0.1 |
| 31,692 | 6.9 | 30,000 | 5.6 | 20,000 | 3.5 | 16,000 | 2.6 | 12,000 | 1.9 | 12,452 | 1.8 |
| 6,398 | 1.4 | 14,976 | 2.8 | 4,721 | .8 | 5,992 | 1.0 | 4,544 | .7 | 4,878 | 0.7 |
| 40,970 | 8.9 | 47,544 | 8.8 | 27,524 | 4.8 | 23,191 | 3.8 | 17,176 | 2.7 | 17,601 | 2.6 |
| 161,755 | 100.0 | 538,279 | 100.0 | 576,315 | 100.0 | 607,710 | 100.0 | 643,944 | 100.0 | 689,681 | 100.0 |
| | 79.5 | | 77.0 | | 75.7 | | 74.6 | | 73.8 | | 73.6 |
| 40,364 | 6.9 | 50,532 | 7.2 | 61,243 | 8.0 | 67,855 | 8.3 | 79,217 | 9.1 | 88,944 | 9.5 |
| 46,169 | 7.9 | 61,935 | 8.9 | 69,876 | 9.2 | 80,184 | 9.8 | 86,594 | 9.9 | 91,167 | 9.7 |
| (16,754) | (2.9) | (20,248) | (2.9) | (23,037) | (3.0) | (26,817) | (3.3) | (30,150) | (3.5) | (35,622) | (3.8) |
| 32,826 | 5.7 | 48,574 | 6.9 | 54,016 | 7.1 | 59,208 | 7.3 | 62,614 | 7.2 | 66,904 | 7.2 |
| 19,359 | 20.5 | 161,041 | 23.0 | 185,135 | 24.3 | 207,247 | 25.4 | 228,425 | 26.2 | 247,015 | 26.4 |
| 581,114 | 100.0 | \$699,320 | 100.0 | \$761,450 | 100.0 | \$814,957 | 100.0 | \$872,369 | 100.0 | \$936,696 | 100.0 |


NCI EXTRAMURAL FUNDS — FISCAL YEAR 1979

Total Extramural
\$756,585,000



Total Intramural (not shown) \$180,111,000
Total NCI \$936,696,000

NCI RESEARCH PROGRAMS — FISCAL YEAR 1979




| Research Programs | Dollars | PERCENT OF TOTAL |
|-------------------------------|----------------------|------------------|
| Research Programs | \$743,689,000 | 79.4 |
| Resource Development | | |
| Cancer Centers Support | 65,809,000 | 7.0 |
| Research Manpower Development | 37,746,000 | 4.0 |
| Construction | 18,176,000 | 2.0 |
| Cancer Control | 71,276,000 | 7.6 |
| Total NCI | \$936,696,000 | 100.0 |

TOTAL NCI DOLLARS BY MECHANISMS — FISCAL YEAR 1979


| | AMOUNT | MECHANISM | PERCENT OF TOTAL | |
|-----------|--|--|------------------|-------|
| | RESEARCH PROJECTS GRANTS | | | |
| \$287,684 | \$183,536 | Research Project Grants | 19.6 | 30.7% |
| | 2,302 | Young Investigators | 0.3 | |
| | 7,894 | Cancer Research Emphasis Grants | 0.8 | |
| | 93,953 | Program Projects | 10.0 | |
| | RESEARCH CENTERS GRANTS | | | |
| \$64,635 | 271 | Exploratory Grants | 0.1 | 6.9% |
| | 64,364 | Center Core Grants | 6.8 | |
| | OTHER RESEARCH GRANTS | | | |
| \$67,879 | 2,000 | Scientific Evaluation | 0.2 | 7.2% |
| | 651 | Conference Grants | 0.1 | |
| | 4,771 | Research Career Programs | 0.5 | |
| | 11,404 | Clinical Education Programs | 1.2 | |
| | 32,021 | Cooperative Clinical Research | 3.4 | |
| | 17,032 | National Organ Site Program | 1.8 | |
| | TRAINING PROGRAM | | | |
| \$20,139 | 3,033 | National Research Service Awards—Individual | 0.3 | 2.1% |
| | 17,106 | National Research Service Awards—Institutional | 1.8 | |
| | RESEARCH AND RESOURCE CONTRACTS | | | |
| \$232,014 | 232,014 | Research and Resource Contracts | 24.8 | 24.8% |
| | CANCER CONTROL | | | |
| \$70,107 | 70,107 | Cancer Control | 7.5 | 7.5% |
| | CONSTRUCTION | | | |
| \$17,330 | 17,330 | Construction | 1.9 | 1.9% |
| | IN-HOUSE | | | |
| \$176,908 | 100,515 | Intramural Research | 10.7 | 18.9% |
| | 65,195 | Direct Operations | 7.0 | |
| | 11,198 | Program Management | 1.2 | |
| | \$936,696 | TOTAL NCI | 100.0 | |

NCI PROGRAM STRUCTURE — FISCAL YEAR 1979

TOTAL DOLLARS
\$936,696,000




CANCER CONTROL PROGRAM OBLIGATIONS — FISCAL YEARS 1973-1979



*No Treatment, Rehabilitation and Continuing Care in FY 1973.

REIMBURSEMENT TO NIH MANAGEMENT FUND FISCAL YEAR 1979

TOTAL NIH SERVICES
\$140,186,000



CLINICAL CENTER

- Employee Health Services
- Service Functions
- Social Work
- Professional Services
- Consultative Services
- Admissions and Follow-up
- Anesthesiology
- Diagnostic X-Ray
- Clinical Pathology
- Blood Bank
- Rehabilitation Service
- Pharmacy Service
- Medical Records
- TV Engineering
- Nursing Service
- Patient Nutrition Service
- Environmental Sanitation Control
- Laundry
- Radiation Safety


STANDARD LEVEL USER CHARGES (SLUC)

- Building usage including utilities
- Major renovations
- Guard services for rental buildings

DIVISION OF RESEARCH GRANTS

- Initial Scientific Review of Applications
- Assignment of Research Grant Applications Among Institutes

DISTRIBUTION OF NCI SERVICES
\$35,662,000



DIVISION OF COMPUTER RESEARCH AND TECHNOLOGY

Research & Development Program in Which Concepts & Methods of Computer Science Are Applied to Biomedical Problems (Services Are Rendered to the NIH Communities on a Fee-For-Service Basis).

\$2,256,000

OFFICE OF ADMINISTRATION

- Division of Administrative Services
- Division of Contracts and Grants
- Division of Engineering Services
- Division of Financial Management
- Division of Management Policy
- Division of Management Survey and Review
- Division of Personnel Management

\$11,911,000


DIVISION OF RESEARCH SERVICES

- Laboratory Aids
- Animal Hospital
- Media Preparation
- Glassware Preparation
- Comparative Pathology
- Germ-free Animal Production
- Biomedical Engineering and Instrumentation
- Library Services
- Medical Arts
- Environmental Services

\$3,272,000

The Management Fund provides for the financing of certain common research supporting services and administrative activities which are required in the operating of NIH.

NCI GRANTS ADMINISTRATION PROCESS — UNDER CANCER ACT OF 1971




NOTE: SIMULTANEOUS ACTIVITIES BY MORE THAN ONE ORGANIZATION INDICATE COOPERATIVE EFFORTS

LEGEND:

- OPERATIONS
- REVIEW
- ▲ DECISION

- NORMAL ADMINISTRATIVE FLOW
- - - - APPLICATIONS LESS THAN \$35,000 TOTAL COSTS (TIME SAVING 3 TO 4 WEEKS)
- - - - *SITE VISITS REQUIRED FOR ONLY ABOUT 10% OF APPLICATIONS
- - - - **NCAB MEETS NOT LESS THAN FOUR TIMES PER YEAR

NCI CONTRACTS ADMINISTRATION PROCESS — UNDER CANCER ACT OF 1971




NOTE: SIMULTANEOUS ACTIVITIES BY MORE THAN ONE ORGANIZATION INDICATE COOPERATIVE EFFORTS.

LEGEND:

- OPERATION
- REVIEW
- ▲ DECISION
- NORMAL FLOW
- - - NON-COMPETITIVE CONTRACTS
- * AD HOC COMMITTEES MAY BE USED — INCLUDES OUTSIDE SCIENTISTS.

STATE DISTRIBUTION OF GRANTS AND CONTRACTS—FISCAL YEAR 1979


(DOLLARS IN THOUSANDS)



NOTE: Contract figures exclude Foreign Contracts: \$8,218; Grant figures exclude Foreign Grants: \$2,518, and Scientific Evaluation (DRG): \$261.

DISTRIBUTION OF CANCER CONTROL GRANTS AND CONTRACTS — FISCAL YEAR 1979

(DOLLARS IN THOUSANDS)



INSTITUTIONS RECEIVING MORE THAN \$1,000,000 FROM THE NATIONAL CANCER INSTITUTE IN FISCAL YEAR 1979

(DOLLARS IN THOUSANDS)

| NAME OF INSTITUTION | GRANTS | CONTRACTS | CONSTRUCTION | TOTAL | LOCATION |
|--|----------|-----------|--------------|----------|----------------------|
| Alabama, University of | \$ 7,363 | \$ 1,126 | \$ — | \$ 8,489 | Alabama |
| Albany Medical College of Union University | 673 | 513 | — | 1,186 | New York |
| Albert Einstein College of Medicine | 7,724 | 168 | — | 7,892 | New York |
| Allegheny-Singer Research Corporation | 893 | 247 | — | 1,140 | Pennsylvania |
| American College of Radiology | 2,478 | 629 | — | 3,107 | Illinois |
| American Health Foundation | 2,661 | 802 | — | 3,463 | New York |
| Arizona, University of | 3,668 | 476 | — | 4,144 | Arizona |
| Army, Department of, Ft. Detrick | — | 3,053 | — | 3,053 | Maryland |
| ARS/Sprague-Dawley | — | 1,039 | — | 1,039 | Wisconsin |
| Arthur D. Little, Inc. | — | 3,015 | — | 3,015 | Massachusetts |
| Assoc. Veterinary Med. Data Program Participants, Inc. | — | 1,165 | — | 1,165 | Illinois |
| Battelle Memorial Institute | — | 4,287 | — | 4,287 | Ohio |
| Baylor College of Medicine | 4,598 | 1,729 | — | 6,327 | Texas |
| Ben Venue Laboratories, Inc. | — | 1,050 | — | 1,050 | Ohio |
| Boston University Medical Center | 1,395 | 112 | — | 1,507 | Massachusetts |
| Bowman Gray School of Medicine of Wake Forest Univ. | 1,417 | 105 | — | 1,522 | North Carolina |
| California Institute of Technology | 367 | 45 | 1,530 | 1,942 | California |
| California State Department of Health | 116 | 1,549 | — | 1,665 | California |
| California, University of | 28,646 | 7,627 | 1,983 | 38,256 | California |
| Cancer Research Center | 2,390 | 511 | — | 2,901 | Missouri |
| Case Western Reserve University | 2,145 | 329 | — | 2,474 | Ohio |
| Charles River Breeding Labs | — | 2,829 | — | 2,829 | Massachusetts |
| Chicago, University of | 6,490 | 944 | — | 7,434 | Illinois |
| Children's Hospital Medical Center | 1,823 | — | — | 1,823 | Massachusetts |
| Children's Hospital of Philadelphia | 915 | 438 | — | 1,353 | Pennsylvania |
| Cincinnati, University of | 1,072 | 363 | — | 1,435 | Ohio |
| City of Hope National Medical Center | 1,021 | — | — | 1,021 | California |
| Cold Spring Harbor Laboratory | 3,102 | — | — | 3,102 | New York |
| College of Medicine and Dentistry of New Jersey | 945 | 322 | — | 1,267 | New Jersey |
| Colorado State University | 1,394 | — | — | 1,394 | Colorado |
| Colorado, University of, Medical Center | 2,141 | 241 | — | 2,382 | Colorado |
| Columbia University | 7,242 | 1,724 | — | 8,966 | New York |
| Connecticut, University of | 1,324 | 71 | — | 1,395 | Connecticut |
| Cornell University | 2,634 | 559 | — | 3,193 | New York |
| Dartmouth College | 2,004 | 512 | — | 2,516 | New Hampshire |
| Duke University | 6,925 | 2,020 | — | 8,945 | North Carolina |
| Electro-Nucleonics Laboratories, Inc. | — | 1,256 | — | 1,256 | Maryland |
| Emory University | 1,521 | 1,469 | — | 2,990 | Georgia |
| Energy, Department of | 929 | 4,285 | — | 5,214 | New York |
| Enviro Control, Inc. | — | 4,424 | — | 4,424 | Maryland |
| Florida, University of | 1,049 | 551 | — | 1,600 | Florida |
| Fox Chase Cancer Center | 818 | 416 | — | 1,234 | Pennsylvania |
| Fred Hutchinson Cancer Research Center | 8,549 | 1,469 | — | 10,018 | Washington |
| George Washington University | 1,698 | 104 | — | 1,802 | District of Columbia |
| Georgetown University | 1,468 | 1,056 | — | 2,524 | District of Columbia |
| Georgia, University of | 1,098 | 149 | — | 1,247 | Georgia |
| Hahnemann Medical College and Hospital | 1,629 | 259 | — | 1,888 | Pennsylvania |
| Harlan Industries, Inc. | — | 1,882 | — | 1,882 | Indiana |
| Harvard University | 8,255 | 608 | — | 8,863 | Massachusetts |
| Hawaii, University of | 1,151 | 1,608 | 27 | 2,786 | Hawaii |
| Hazleton Laboratories, Inc. | — | 2,403 | — | 2,403 | Virginia |
| Health Research, Inc. | 11,356 | 1,224 | — | 12,580 | New York |
| Howard University | 1,117 | 240 | — | 1,357 | District of Columbia |
| IIT Research Institute | 63 | 3,405 | — | 3,468 | Illinois |
| Illinois Cancer Council | 742 | 837 | — | 1,579 | Illinois |
| Illinois, University of | 1,377 | — | — | 1,377 | Illinois |
| Indian Health Service | — | 8,882 | — | 8,882 | Alaska |
| Indiana University-Purdue University at Indianapolis | 1,043 | — | — | 1,043 | Indiana |
| Institute for Cancer Research | 6,772 | 310 | — | 7,082 | Pennsylvania |
| Iowa, University of | 2,322 | 1,654 | — | 3,976 | Iowa |
| Jackson Laboratory | 1,129 | 458 | — | 1,587 | Maine |
| Jefferson Medical College | 2,851 | 634 | — | 3,485 | Pennsylvania |
| Johns Hopkins University | 12,304 | 2,960 | 2,595 | 17,859 | Maryland |
| Kaiser Foundation Research Institute | 181 | 932 | — | 1,113 | California |
| Kansas, University of, Medical Center | 2,642 | 1,063 | — | 3,705 | Kansas |
| Kentucky, University of | 2,024 | 266 | — | 2,290 | Kentucky |
| La Jolla Cancer Research Foundation | 1,143 | 1 | — | 1,144 | California |
| Life Sciences, Inc. | 86 | 1,680 | — | 1,766 | Florida |
| Litton Bionetics, Inc. | — | 31,988 | 2,594 | 34,582 | Maryland |
| Long Island Cancer Council | — | 1,682 | — | 1,682 | New York |
| Maryland, University of | 921 | 4,633 | — | 5,554 | Maryland |
| Mason Research Institute | — | 4,381 | — | 4,381 | Massachusetts |
| Massachusetts General Hospital | 4,981 | 1,677 | — | 6,658 | Massachusetts |

| NAME OF INSTITUTION | GRANTS | CONTRACTS | CONSTRUCTION | TOTAL | LOCATION |
|---|----------|-----------|--------------|----------|----------------------|
| Massachusetts Institute of Technology | \$ 5,441 | \$ 256 | \$ - | \$ 5,697 | Massachusetts |
| Mayo Foundation | 3,108 | 5,037 | - | 8,145 | Minnesota |
| Medical College of Wisconsin | 961 | 140 | - | 1,101 | Wisconsin |
| Meloy Laboratories, Inc. | - | 3,937 | - | 3,937 | Virginia |
| Memorial Hospital for Cancer and Allied Diseases | 3,667 | 2,713 | - | 6,380 | New York |
| Miami, University of | 3,276 | 884 | - | 4,160 | Florida |
| Michigan Cancer Foundation | 2,240 | 2,362 | 769 | 5,371 | Michigan |
| Michigan State University | 1,644 | 236 | - | 1,880 | Michigan |
| Michigan, University of | 1,979 | 475 | - | 2,454 | Michigan |
| Microbiological Associates | - | 2,801 | - | 2,801 | Maryland |
| Midwest Research Institute | 91 | 2,679 | - | 2,770 | Missouri |
| Minnesota, University of | 5,144 | 1,544 | - | 6,688 | Minnesota |
| Montefiore Hospital and Medical Center | 517 | 522 | - | 1,039 | New York |
| Mount Sinai School of Medicine | 5,786 | 1,149 | - | 6,935 | New York |
| Nebraska, University of | 1,561 | 2,306 | - | 3,867 | Nebraska |
| New Mexico, University of | 4,720 | 2,389 | - | 7,109 | New Mexico |
| New York Medical College | 999 | 257 | - | 1,256 | New York |
| New York University Medical Center | 5,257 | 508 | - | 5,765 | New York |
| North Carolina, University of | 2,672 | 363 | 1,373 | 4,408 | North Carolina |
| Northern California Cancer Program | 3,256 | 346 | - | 3,602 | California |
| Northwestern University | 1,878 | 122 | - | 2,000 | Illinois |
| Ohio State University Research Foundation | 4,252 | 1,043 | - | 5,295 | Ohio |
| Ontario Cancer Institute | 31 | 994 | - | 1,025 | Canada |
| Oregon State University | 1,793 | 43 | - | 1,836 | Oregon |
| Pennsylvania State University | 1,600 | 1,205 | - | 2,805 | Pennsylvania |
| Pennsylvania, University of | 6,310 | 795 | - | 7,105 | Pennsylvania |
| Peter Bent Brigham Hospital | 749 | 485 | - | 1,234 | Massachusetts |
| Pfizer, Inc. | - | 2,175 | - | 2,175 | New Jersey |
| Pittsburgh, University of | 1,848 | 2,663 | - | 4,511 | Pennsylvania |
| Purdue Research Foundation | 1,087 | 160 | - | 1,247 | Indiana |
| Research Foundation of the State University of New York | 3,766 | 508 | - | 4,274 | New York |
| Rochester, University of | 5,441 | 534 | - | 5,975 | New York |
| Rockefeller University | 3,607 | - | - | 3,607 | New York |
| Roger Williams General Hospital | 1,304 | - | - | 1,304 | Rhode Island |
| Rush Presbyterian-St. Luke's Medical Center | 1,246 | 676 | - | 1,922 | Illinois |
| Saint Jude Children's Research Hospital | 3,896 | 40 | 1,000 | 4,936 | Tennessee |
| Saint Louis University School of Medicine | 1,091 | 755 | - | 1,846 | Missouri |
| Salk Institute for Biological Studies | 3,383 | 273 | - | 3,656 | California |
| Scripps Clinic and Research Foundation | 2,937 | 687 | - | 3,624 | California |
| Sidney Farber Cancer Institute | 13,232 | 1,165 | - | 14,397 | Massachusetts |
| Simonsen Labs, Inc. | - | 1,374 | - | 1,374 | California |
| Sloan-Kettering Institute for Cancer Research | 18,342 | 1,872 | 3,175 | 23,389 | New York |
| Southern California, University of | 8,314 | 3,348 | - | 11,662 | California |
| Southern Research Institute | 2,232 | 3,592 | - | 5,824 | Alabama |
| SRI International | 1,190 | 4,017 | - | 5,207 | California |
| Stanford University | 9,254 | 1,227 | - | 10,481 | California |
| Temple University | 4,019 | 327 | - | 4,346 | Pennsylvania |
| Tennessee, University of | 1,364 | 152 | - | 1,516 | Tennessee |
| Texas, University of, Health Science Center | 19,496 | 3,998 | - | 23,494 | Texas |
| Tracor Jitco, Inc. | - | 13,378 | - | 13,378 | Maryland |
| Tufts University | 2,218 | 47 | - | 2,265 | Massachusetts |
| Tufts-New England Medical Center | 1,455 | - | - | 1,455 | Massachusetts |
| U. S. Environmental Protection Agency | - | 2,114 | - | 2,114 | District of Columbia |
| Utah, University of | 3,254 | 468 | - | 3,722 | Utah |
| Vanderbilt University Medical Center | 1,445 | 699 | - | 2,144 | Tennessee |
| Vermont, University of, College of Medicine | 2,053 | 277 | - | 2,330 | Vermont |
| Veterans Administration | - | 2,402 | - | 2,402 | District of Columbia |
| Veterans Administration Hospital | 365 | 1,464 | - | 1,829 | New Jersey |
| Virginia Commonwealth University | 1,935 | - | - | 1,935 | Virginia |
| Virginia, University of | 1,199 | 91 | - | 1,290 | Virginia |
| Warner Lampert | - | 1,010 | - | 1,010 | Michigan |
| Washington University | 4,844 | 215 | - | 5,059 | Missouri |
| Washington, University of | 2,730 | 4,439 | - | 7,169 | Washington |
| Wayne State University | 1,631 | 852 | - | 2,483 | Michigan |
| Westat, Inc. | - | 1,622 | - | 1,622 | Maryland |
| Wisconsin, University of | 12,331 | 1,117 | - | 13,448 | Wisconsin |
| Wistar Institute of Anatomy and Biology | 5,647 | - | - | 5,647 | Pennsylvania |
| Worcester Foundation for Experimental Biology | 1,478 | - | - | 1,478 | Massachusetts |
| Yale University School of Medicine | 11,161 | 1,116 | - | 12,277 | Connecticut |

| | | | | |
|---|------------------|------------------|-----------------|------------------|
| TOTALS | \$416,512 | \$226,891 | \$15,046 | \$658,449 |
| PERCENT OF TOTAL AWARDED ABOVE | 63.2 | 34.5 | 2.3 | 100 |
| TOTAL NCI FISCAL YEAR 1979 OBLIGATIONS | \$936,696 | | | |
| PERCENT OF NCI TOTAL OBLIGATIONS | 44.5 | 24.2 | 1.6 | 70.3 |

NOTE: The NCI funds approximately 635 institutions; therefore, the above listing represents about 23 percent of the institutions annually funded by NCI.

DISTRIBUTION OF NCI CONTRACTS — FISCAL YEAR 1979

PROGRAM DISTRIBUTION

| PERCENT OF TOTAL NUMBER OF CONTRACTS | NUMBER OF CONTRACTS | NCI PROGRAM AREA | THOUSANDS OF DOLLARS | PERCENT OF TOTAL DOLLARS |
|---|------------------------|--|-------------------------|-----------------------------|
| 20.0 | 199 | Division of Cancer Biology and Diagnosis | \$ 29,683 | 10.7 |
| 26.0 | 259 | Division of Cancer Treatment | 79,152 | 28.6 |
| 37.5 | 373 | Division of Cancer Cause and Prevention | 119,427 | 43.0 |
| 15.0 | 149 | Division of Cancer Control and Rehabilitation | 45,045 | 16.3 |
| 1.5 | 15 | Office of the Director | 3,752 | 1.4 |

Includes Interagency Agreements

995

TOTALS

\$277,059

INSTITUTIONAL DISTRIBUTION

| PERCENT OF TOTAL NUMBER OF CONTRACTS | NUMBER OF CONTRACTS | TYPE OF INSTITUTION | THOUSANDS OF DOLLARS | PERCENT OF TOTAL DOLLARS |
|---|------------------------|----------------------------|-------------------------|-----------------------------|
| 18.5 | 184 | Profit-Making | \$101,614 | 36.7 |
| 40.1 | 398 | Academic | 77,082 | 27.8 |
| 24.6 | 245 | Non-Profit | 59,603 | 21.5 |
| 6.4 | 64 | Federal Government | 24,357 | 8.8 |
| 3.0 | 30 | State and Local Government | 6,185 | 2.2 |
| 7.4 | 74 | Foreign | 8,218 | 3.0 |

995


TOTALS

\$277,059

NOTE: Does not include contracts that are not in direct support of research or control, such as the International Cancer Research Data Bank, Cancer Communications, and Program Planning. Construction contracts are also excluded.

DISTRIBUTION OF NCI RESEARCH GRANTS BY VALUE OF GRANT AWARD – FISCAL YEAR 1979

TOTAL GRANT DOLLARS
\$404,023,000
2,832 GRANTS




Excludes Training and Fellowship Awards, Cancer Control Grants, Construction Grants, Clinical Education, and Career Awards. Includes Clinical Trials and CREG Awards.

DISTRIBUTION OF THE GRANT DOLLAR — FISCAL YEAR 1979

(DOLLARS IN THOUSANDS)

TOTAL GRANT OBLIGATIONS
\$474,648



**FOREIGN RESEARCH GRANTS AND
CONTRACTS — FISCAL YEAR 1979**

| | NUMBER OF GRANTS | GRANT DOLLARS AWARDED | NUMBER OF CONTRACTS | CONTRACT DOLLARS AWARDED | TOTAL DOLLARS AWARDED | PERCENT OF TOTAL AMOUNT AWARDED |
|--------------------|------------------------|-----------------------------|---------------------------|--------------------------------|-----------------------------|---------------------------------------|
| Australia | 6 | \$ 281,124 | 2 | \$ 106,790 | \$ 387,914 | 3.7 |
| Austria | — | — | 2 | 109,100 | 109,100 | 1.0 |
| Belgium | 1 | 298,058 | 2 | 302,400 | 600,458 | 5.6 |
| Canada | 12 | 514,704 | 9 | 1,418,342 | 1,933,046 | 18.2 |
| Denmark | 1 | 30,500 | — | — | 30,500 | 0.3 |
| England | 4 | 299,593 | 8 | 783,435 | 1,083,028 | 10.2 |
| Finland | 2 | 72,200 | 2 | 63,080 | 135,280 | 1.3 |
| France | 1 | 33,330 | 7 | 1,181,695 | 1,215,025 | 11.4 |
| Germany | 1 | 43,657 | 1 | 74,100 | 117,757 | 1.1 |
| Ghana | — | — | 1 | 58,365 | 58,365 | 0.5 |
| Israel | 7 | 369,031 | 13 | 1,347,812 | 1,716,843 | 16.2 |
| Italy | 1 | 44,000 | 6 | 772,883 | 816,883 | 7.7 |
| Japan | — | — | 6 | 624,110 | 624,110 | 5.9 |
| Korea, Republic of | 1 | 11,430 | — | — | 11,430 | 0.1 |
| Netherlands | — | — | 4 | 306,685 | 306,685 | 2.9 |
| Norway | — | — | 1 | 82,186 | 82,186 | 0.8 |
| Scotland | — | — | 3 | 268,537 | 268,537 | 2.5 |
| South Africa | 1 | 56,120 | — | — | 56,120 | 0.5 |
| Sweden | 3 | 250,523 | 6 | 708,423 | 958,946 | 9.0 |
| Switzerland | 1 | 106,103 | — | — | 106,103 | 1.0 |
| Uganda | — | — | 1 | 9,975 | 9,975 | 0.1 |
| TOTAL | 42 | \$2,410,373 | 74 | \$8,217,918 | \$10,628,291 | 100.0 |

APPROPRIATIONS OF THE NCI 1938-1980

| | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|----------------------------|---|---|------------|----------------|---|--|------------|-------------|------------|-------------|------------|-------------|------------|--------------------------|------------|--------------------------|------------|-------------|------------|-------------|------------|--------------------------|------------|----------------------------|
| 1938 | \$ 400,000 | } | | | | | | | | | | | | | | | | | | | | | | | |
| 1939 | 400,000 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1940 THROUGH 1946 \$3,879,570 | | } | 0.23% \$21,000,470 | | | | | | | | | | | | | | | | | | | | | | |
| 1947 | 1,820,900 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1948 | 14,500,000 | } | | | | | | | | | | | | | | | | | | | | | | | |
| 1949 | 22,000,000 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1950 THROUGH 1956 \$149,481,750 | | } | 3.09% \$276,315,750 | | | | | | | | | | | | | | | | | | | | | | |
| 1957 | 48,432,000 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1958 | 56,402,000 | } | | | | | | | | | | | | | | | | | | | | | | | |
| 1959 | 75,268,000 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1960 THROUGH 1966 \$958,954,000 | | } | 15.57% \$1,393,234,000 | | | | | | | | | | | | | | | | | | | | | | |
| 1967 | 175,656,000 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1968 | 183,356,000 | } | | | | | | | | | | | | | | | | | | | | | | | |
| 1969 | 185,149,500 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1970 | 190,486,063 | } | 6.77% \$606,018,563 | | | | | | | | | | | | | | | | | | | | | | |
| 1971 | 230,383,000 | | | | | | | | | | | | | | | | | | | | | | | | |
| <table style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td style="width: 60%;">1972</td> <td style="width: 20%; text-align: right;">\$ 378,794,000</td> <td rowspan="10" style="width: 20%; vertical-align: middle;">}</td> <td rowspan="10" style="width: 20%;"></td> </tr> <tr> <td>1973</td> <td style="text-align: right;">492,205,000</td> </tr> <tr> <td>1974</td> <td style="text-align: right;">551,191,500</td> </tr> <tr> <td>1975</td> <td style="text-align: right;">691,666,000</td> </tr> <tr> <td>1976</td> <td style="text-align: right;">761,727,000¹</td> </tr> <tr> <td>“TQ”</td> <td style="text-align: right;">152,901,000²</td> </tr> <tr> <td>1977</td> <td style="text-align: right;">815,000,000</td> </tr> <tr> <td>1978</td> <td style="text-align: right;">872,388,000</td> </tr> <tr> <td>1979</td> <td style="text-align: right;">937,129,000³</td> </tr> <tr> <td>1980</td> <td style="text-align: right;">1,000,000,000⁴</td> </tr> </tbody> </table> | | | | 1972 | \$ 378,794,000 | } | | 1973 | 492,205,000 | 1974 | 551,191,500 | 1975 | 691,666,000 | 1976 | 761,727,000 ¹ | “TQ” | 152,901,000 ² | 1977 | 815,000,000 | 1978 | 872,388,000 | 1979 | 937,129,000 ³ | 1980 | 1,000,000,000 ⁴ |
| 1972 | \$ 378,794,000 | } | | | | | | | | | | | | | | | | | | | | | | | |
| 1973 | 492,205,000 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1974 | 551,191,500 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1975 | 691,666,000 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1976 | 761,727,000 ¹ | | | | | | | | | | | | | | | | | | | | | | | | |
| “TQ” | 152,901,000 ² | | | | | | | | | | | | | | | | | | | | | | | | |
| 1977 | 815,000,000 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1978 | 872,388,000 | | | | | | | | | | | | | | | | | | | | | | | | |
| 1979 | 937,129,000 ³ | | | | | | | | | | | | | | | | | | | | | | | | |
| 1980 | 1,000,000,000 ⁴ | | | | | | | | | | | | | | | | | | | | | | | | |
| 74.34% | | } | \$6,653,001,500 | | | | | | | | | | | | | | | | | | | | | | |
| \$6,653,001,500 | | | | | | | | | | | | | | | | | | | | | | | | | |
| TOTAL (1938 through 1980) | | | \$8,949,570,283 | | | | | | | | | | | | | | | | | | | | | | |

NOTEWORTHY DATES FOR NCI APPROPRIATIONS

Exceeded \$1,000,000 in 1947. Exceeded \$50,000,000 in 1958.
Exceeded \$100,000,000 in 1961. Exceeded \$1,000,000,000 in 1980.

TRANSITION QUARTER (“TQ”)—July 1, 1976 through September 30, 1976—The Interim Period in the changing of the Federal Fiscal Year from July 1 through June 30, to October 1 through September 30.

¹Includes \$18,163,000 for training funds provided by Continuing Resolution.


²Includes \$3,201,000 for training funds provided by Continuing Resolution.

³Included \$20,129,000 for training funds provided by Continuing Resolution.

⁴1980 appropriation authorized under a Continuing Resolution.

DISTRIBUTION OF PERSONNEL BY FUNCTION

| Percent of Actual Employment | | | | | | | | | | |
|--------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| | FISCAL YEAR | | | | | | | | | |
| | 1970 | 1971 | 1972 | 1973 | 1974 | 1975 | 1976 | 1977 | 1978 | 1979 |
| Scientific | 38.3% | 37.5% | 36.2% | 37.3% | 34.4% | 32.7% | 37.9% | 41.7% | 43.8% | 44.9% |
| Administrative | 24.0% | 23.9% | 27.3% | 27.6% | 27.0% | 30.0% | 30.7% | 27.2% | 25.3% | 26.6% |
| Technical and Supporting | 37.7% | 38.6% | 36.5% | 35.1% | 38.6% | 37.3% | 31.4% | 31.1% | 30.9% | 28.5% |
| Total Actual Employment | 1355 | 1426 | 1665 | 1736 | 1805 | 1849 | 1955 | 1986 | 1969 | 1973 |




COMPARISON OF DOLLARS, POSITIONS AND SPACE

| FISCAL YEAR | DOLLARS | | | POSITIONS | | | SPACE | | |
|-------------|-----------------------|------------------------------------|-------------------------------------|--------------------------------------|------------------------------------|-------------------------------------|--------------------------------|------------------------------------|-------------------------------------|
| | OBLIGATIONS (\$000's) | PERCENT OF INCREASE OVER BASE YEAR | PERCENT OF INCREASE OVER PRIOR YEAR | ACTUAL FULL-TIME PERMANENT EMPLOYEES | PERCENT OF INCREASE OVER BASE YEAR | PERCENT OF INCREASE OVER PRIOR YEAR | ALLOCATED SPACE (SQUARE FEET)* | PERCENT OF INCREASE OVER BASE YEAR | PERCENT OF INCREASE OVER PRIOR YEAR |
| 1971 | 232,855 | Base Year | — | 1426 | Base Year | — | 321,230 | Base Year | — |
| 1972 | 378,636 | 62.6 | 62.6 | 1665 | 16.8 | 16.8 | 329,587 | 2.6 | 2.6 |
| 1973 | 431,245 | 85.2 | 13.9 | 1736 | 21.7 | 4.3 | 357,972 | 11.4 | 8.6 |
| 1974 | 581,149 | 149.6 | 34.8 | 1805 | 26.6 | 4.0 | 381,436 | 18.7 | 6.6 |
| 1975 | 699,320 | 200.3 | 20.3 | 1849 | 29.7 | 2.4 | 382,485 | 19.1 | 0.2 |
| 1976 | 760,751 | 226.7 | 8.8 | 1955 | 37.1 | 5.7 | 387,324 | 20.6 | 1.3 |
| 1977 | 814,957 | 250.0 | 7.1 | 1986 | 39.3 | 1.6 | 428,285 | 33.3 | 10.6 |
| 1978 | 872,369 | 275.0 | 7.2 | 1969 | 38.1 | -0.9 | 491,725 | 53.1 | 14.8 |
| 1979 | 936,696 | 302.3 | 7.4 | 1973 | 38.4 | 0.2 | 493,156 | 53.5 | 0.3 |


*Does not include field station assigned space.

NATIONAL CANCER INSTITUTE OBLIGATIONS AND OUTLAYS



OBLIGATIONS: Orders placed, grants and contracts awarded, salaries earned and similar financial transactions which legally utilize or reserve an appropriation for expenditure.

OUTLAYS: Payments (cash or checks) made from current or prior year appropriations.

NCI GRANT AWARDS — 1970-1979

*Includes Clinical Education and Research Career Program.

NCI REGULAR GRANT AWARDS — 1973-1979 (Including Clinical Cooperative Groups)

(DOLLARS IN THOUSANDS)

| FISCAL YEAR | TYPE AWARD | REQUESTED | | APPROVED | | AWARDED | | PERCENT FUNDED |
|-------------|---------------------|--------------|----------------|--------------|----------------|------------|---------------|----------------|
| | | NUMBER | AMOUNT | NUMBER | AMOUNT | NUMBER | AMOUNT | |
| 1973 | Competing | | | | | | | |
| | New | 1,258 | \$ 84,946 | 715 | \$ 33,794 | 372 | \$ 18,085 | 52.0 |
| | Renewals | 217 | 21,906 | 189 | 13,363 | 129 | 10,365 | 68.3 |
| | Total | 1,475 | 106,852 | 904 | 47,157 | 501 | 28,450 | 55.4 |
| | Non-Competing | — | — | — | — | 1,013 | 54,687 | — |
| 1974 | Competing | | | | | | | |
| | New | 1,382 | \$100,717 | 909 | \$ 45,713 | 500 | \$ 27,824 | 55.0 |
| | Renewals | 379 | 33,651 | 336 | 22,815 | 285 | 20,413 | 84.8 |
| | Total | 1,761 | 134,368 | 1,245 | 68,528 | 785 | 48,237 | 63.1 |
| | Non-Competing | — | — | — | — | 1,049 | 62,803 | — |
| 1975 | Competing | | | | | | | |
| | New | 1,509 | \$108,621 | 979 | \$ 48,023 | 581 | \$ 30,605 | 59.3 |
| | Renewals | 555 | 55,314 | 429 | 31,876 | 349 | 27,949 | 81.4 |
| | Total | 2,064 | 163,935 | 1,408 | 79,899 | 930 | 58,554 | 66.1 |
| | Non-Competing | — | — | — | — | 1,112 | 72,917 | — |
| 1976 | Competing | | | | | | | |
| | New | 1,499 | \$113,135 | 910 | \$ 47,342 | 388 | \$ 22,230 | 42.6 |
| | Renewals | 517 | 53,992 | 376 | 28,070 | 257 | 21,236 | 68.4 |
| | Total | 2,016 | 167,127 | 1,286 | 75,412 | 645 | 43,466 | 50.2 |
| | Non-Competing | — | — | — | — | 1,486 | 108,818 | — |
| 1977 | Competing | | | | | | | |
| | New | 1,756 | 147,591 | 1,071 | \$ 60,155 | 398 | \$ 23,781 | 37.2 |
| | Renewals | 728 | 87,162 | 578 | 50,221 | 303 | 32,436 | 52.4 |
| | Total | 2,484 | 234,753 | 1,649 | 110,376 | 701 | 56,217 | 42.5 |
| | Non-Competing | — | — | — | — | 1,412 | 104,431 | — |
| 1978 | Competing | | | | | | | |
| | New | 1,854 | \$153,528 | 1,264 | \$ 75,014 | 513 | \$ 32,591 | 40.6 |
| | Renewals | 752 | 97,937 | 617 | 57,131 | 381 | 38,905 | 61.8 |
| | Total | 2,606 | 251,465 | 1,881 | 132,145 | 894 | 71,496 | 47.5 |
| | Non-Competing | — | — | — | — | 1,341 | 111,916 | — |
| 1979 | Competing | | | | | | | |
| | New | 1,950 | \$177,989 | 1,414 | \$ 97,596 | 576 | \$ 45,287 | 40.7 |
| | Renewals | 653 | 80,521 | 570 | 52,012 | 334 | 35,025 | 58.6 |
| | Total | 2,603 | 258,510 | 1,984 | 149,608 | 910 | 80,312 | 45.9 |
| | Non-Competing | — | — | — | — | 1,485 | 141,198 | — |

NIH Publication No. 80-512
April 1980